TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION: Form 990, tax year 2010

View the entire original 990 at ProPublica ↗

Organization: TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION (EIN 33-1092191)
Tax period: 2010-12-01 to 2011-11-30
Filed: 2012-10-15
IRS object ID: 201202899349300955
Schema version: 2010v3.7
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule D
Schedule I
Schedule J
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Timestamp	2012-10-15T13:29:19-05:00	Timestamp
Tax Period End Date	2011-11-30	TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	ERNST & YOUNG US LLP	BusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

Field	Value	IRS element (for citing)
Address Line1	TWO NORTH CENTRAL AVENUE STE 2300	AddressLine1
City	PHOENIX	City
State	AZ	State
ZIP Code	85004	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnType
Tax Period Begin Date	2010-12-01	TaxPeriodBeginDate

Filer Filer

Field	Value	IRS element (for citing)
EIN	331092191	EIN

Name Name

Field	Value	IRS element (for citing)
Business Name Line1	THE TRANSLATIONAL GENOMICS RESEARCH INST FDN	BusinessNameLine1

Field	Value	IRS element (for citing)
Name Control	TRAN	NameControl
Phone	6023438423	Phone

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	400 E VAN BUREN SUITE 850	AddressLine1
City	PHOENIX	City
State	AZ	State
ZIP Code	85004	ZIPCode

Officer Officer

Field	Value	IRS element (for citing)
Name	abc	Name
Title	abc	Title
Date Signed	2012-10-15	DateSigned

Preparer Preparer

Field	Value	IRS element (for citing)
Phone	6023223000	Phone

Field	Value	IRS element (for citing)
Tax Year	2010	TaxYear
Build TS	2016-02-24 21:20:13Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Name Of Principal Officer Person	MICHAEL BASSOFF	NameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

Field	Value	IRS element (for citing)
Address Line1	SAME AS C ABOVE	AddressLine1
City	PHOENIX	City
State	AZ	State
ZIP Code	85004	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	6025718	GrossReceipts
Group Return For Affiliates	false	GroupReturnForAffiliates
Organization501c3	X	Organization501c3
Web Site	WWW.HELPTGEN.ORG	WebSite
Type Of Organization Corporation	X	TypeOfOrganizationCorporation
Year Formation	2004	YearFormation
State Legal Domicile	AZ	StateLegalDomicile
Activity Or Mission Description	BIOGENOMIC MEDICAL RESEARCH FUNDRAISING FOR THE TRANSLATIONAL GENOMICS RESEARCH INSITUTE (TGEN)	ActivityOrMissionDescription
Nbr Voting Members Governing Body	19	NbrVotingMembersGoverningBody
Nbr Independent Voting Members	15	NbrIndependentVotingMembers
Total Nbr Employees	0	TotalNbrEmployees
Total Nbr Volunteers	145	TotalNbrVolunteers
Total Gross UBI	0	TotalGrossUBI
Net Unrelated Business Txbl Income	0	NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year	64426	ContributionsGrantsPriorYear
Contributions Grants Current Year	5881499	ContributionsGrantsCurrentYear
Program Service Revenue Prior Year	0	ProgramServiceRevenuePriorYear
Program Service Revenue CY	0	ProgramServiceRevenueCY
Investment Income Prior Year	10552	InvestmentIncomePriorYear
Investment Income Current Year	142156	InvestmentIncomeCurrentYear
Other Revenue Prior Year	271	OtherRevenuePriorYear
Other Revenue Current Year	2063	OtherRevenueCurrentYear
Total Revenue Prior Year	75249	TotalRevenuePriorYear
Total Revenue Current Year	6025718	TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year	6338185	GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY	6629446	GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year	0	BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY	0	BenefitsPaidToMembersCY
Salaries Etc Prior Year	364065	SalariesEtcPriorYear
Salaries Etc Current Year	879547	SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year	0	TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY	0	TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year	1150831	TotalFundrsngExpCurrentYear
Other Expense Prior Year	157428	OtherExpensePriorYear
Other Expenses Current Year	587250	OtherExpensesCurrentYear
Total Expenses Prior Year	6859678	TotalExpensesPriorYear
Total Expenses Current Year	8096243	TotalExpensesCurrentYear
Revenues Less Expenses Prior Year	-6784429	RevenuesLessExpensesPriorYear
Revenues Less Expenses CY	-2070525	RevenuesLessExpensesCY
Total Assets BOY	10351117	TotalAssetsBOY
Total Assets EOY	9909027	TotalAssetsEOY
Total Liabilities BOY	669421	TotalLiabilitiesBOY
Total Liabilities EOY	2297856	TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY	9681696	NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY	7611171	NetAssetsOrFundBalancesEOY
Info In Schedule O Part III	X	InfoInScheduleOPartIII
Mission Description	BIOGENOMIC MEDICAL RESEARCH FUNDRAISING FOR THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN).	MissionDescription
Significant New Program Services	false	SignificantNewProgramServices
Significant Change	false	SignificantChange
Expense	6629446	Expense
Grants	6629446	Grants
Description	SEE SCHEDULE O	Description
Total Program Service Expense	6629446	TotalProgramServiceExpense
Described In501 C3	true	DescribedIn501C3
Schedule B Required	true	ScheduleBRequired
Political Activities	false	PoliticalActivities
Lobbying Activities	false	LobbyingActivities
Subject To Proxy Tax	false	SubjectToProxyTax
Donor Advised Funds	false	DonorAdvisedFunds
Conservation Easements	false	ConservationEasements
Collections Of Art	false	CollectionsOfArt
Credit Counseling	false	CreditCounseling
Term Or Permanent Endowments	true	TermOrPermanentEndowments
Report Land Bldg Equip	true	ReportLandBldgEquip
Report Invest Oth Securities	false	ReportInvestOthSecurities
Report Prog Rel Invest	false	ReportProgRelInvest
Report Other Assets	false	ReportOtherAssets
Report Other Liabilities	false	ReportOtherLiabilities
Report Fin48 Footnote	true	ReportFin48Footnote
Independent Audit Financial Stmt	false	IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt	true	ConsolidatedAuditFinancialStmt
School	false	School
Foreign Office	false	ForeignOffice
Foreign Activities	false	ForeignActivities
More Than5000 K To Organizations	false	MoreThan5000KToOrganizations
More Than5000 K To Individuals	false	MoreThan5000KToIndividuals
Professional Fundraising	false	ProfessionalFundraising
Fundraising Activities	false	FundraisingActivities
Gaming	false	Gaming
Hospital	false	Hospital
Grants To Organizations	true	GrantsToOrganizations
Grants To Individuals	false	GrantsToIndividuals
Schedule J Required	true	ScheduleJRequired
Tax Exempt Bonds	false	TaxExemptBonds
Excess Benefit Transaction	false	ExcessBenefitTransaction
Prior Excess Benefit Transaction	false	PriorExcessBenefitTransaction
Loan To Officer Or DQP	false	LoanToOfficerOrDQP
Grant To Related Person	false	GrantToRelatedPerson
Bsnss Rltnshp With Organization	false	BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member	false	BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp	false	OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions	false	DeductibleNonCashContributions
Deductible Contributions Of Art	false	DeductibleContributionsOfArt
Terminated	false	Terminated
Partial Liquidation	false	PartialLiquidation
Disregarded Entity	false	DisregardedEntity
Related Entity	true	RelatedEntity
Related Org Controlled Entity	false	RelatedOrgControlledEntity
Transaction Related Entity	false	TransactionRelatedEntity
Transfers To Exempt Non Chrtbl Org	false	TransfersToExemptNonChrtblOrg
Activities Conducted Partnership	false	ActivitiesConductedPartnership
Schedule O Required	true	ScheduleORequired
Number Forms Transmitted With1096	4	NumberFormsTransmittedWith1096
Number W2 G Included	0	NumberW2GIncluded
Compliance With Backup Witholding	true	ComplianceWithBackupWitholding
Number Of Employees	0	NumberOfEmployees
Unrelated Business Income	false	UnrelatedBusinessIncome
Foreign Financial Account	false	ForeignFinancialAccount
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTrans
Taxable Party Notification	false	TaxablePartyNotification
Non Deductible Contributions	false	NonDeductibleContributions
Quid Pro Quo Contributions	false	QuidProQuoContributions
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOf
Funds To Pay Premiums	false	FundsToPayPremiums
Premiums Paid	false	PremiumsPaid
Indoor Tanning Services	false	IndoorTanningServices
Info In Schedule O Part VI	X	InfoInScheduleOPartVI
Nbr Voting Governing Body Members	19	NbrVotingGoverningBodyMembers
Number Independent Voting Members	15	NumberIndependentVotingMembers
Family Or Business Relationship	false	FamilyOrBusinessRelationship
Delegation Of Management Duties	false	DelegationOfManagementDuties
Changes To Organizing Docs	false	ChangesToOrganizingDocs
Material Diversion Or Misuse	false	MaterialDiversionOrMisuse
Members Or Stockholders	true	MembersOrStockholders
Election Of Board Members	true	ElectionOfBoardMembers
Decisions Subject To Approval	true	DecisionsSubjectToApproval
Minutes Of Governing Body	true	MinutesOfGoverningBody
Minutes Of Committees	true	MinutesOfCommittees
Officer Mailing Address	false	OfficerMailingAddress
Local Chapters	false	LocalChapters
Form990 Provided To Governing Body	true	Form990ProvidedToGoverningBody
Conflict Of Interest Policy	true	ConflictOfInterestPolicy
Annual Disclosure Covered Persons	true	AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement	true	RegularMonitoringEnforcement
Whistleblower Policy	true	WhistleblowerPolicy
Document Retention Policy	true	DocumentRetentionPolicy
Compensation Process CEO	true	CompensationProcessCEO
Compensation Process Other	true	CompensationProcessOther
Investment In Joint Venture	false	InvestmentInJointVenture
States Where Copy Of Return Is Filed	AZ	StatesWhereCopyOfReturnIsFiled
Upon Request	X	UponRequest

The Books Are In Care Of TheBooksAreInCareOf

Field	Value	IRS element (for citing)
Name Person	ELIZABETH MONTEMAYOR	NamePerson
Telephone Number	6023438508	TelephoneNumber

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	400 E VAN BUREN SUITE 850	AddressLine1
City	PHOENIX	City
State	AZ	State
ZIP Code	85004	ZIPCode

Field	Value	IRS element (for citing)
Info In Schedule O Part VII	X	InfoInScheduleOPartVII

Form990 Part VII Section A Form990PartVIISectionA (20 entries)

TitleTitle	Average Hours Per WeekAverageHoursPerWeek	Individual Trustee Or DirectorIndividualTrusteeOrDirector	OfficerOfficer	Reportable Comp From OrganizationReportableCompFromOrganization	Reportable Comp From Related OrgsReportableCompFromRelatedOrgs	Other CompensationOtherCompensation	Highest Compensated EmployeeHighestCompensatedEmployee
MICHAEL BASSOFF
PRESIDENT	24.0	X	X	0	436648	29123
JERRY BISGROVE
BOARD MEMBER	1.0	X		0	0	0
BENNETT DORRANCE
BOARD MEMBER / CHAIRMAN	1.0	X	X	0	0	0
KARL ELLER
BOARD MEMBER	1.0	X		0	0	0
PHIL L FRANCIS
BOARD MEMBER	1.0	X		0	0	0
DIANE HALLE
BOARD MEMBER	1.0	X		0	0	0
LEE T HANLEY
BOARD MEMBER	1.0	X		0	0	0
MIKE INGRAM
BOARD MEMBER	1.0	X		0	0	0
CATHERINE IVY
BOARD MEMBER	1.0	X		0	0	0
KEN KENDRICK
BOARD MEMBER / SECRETARY	1.0	X	X	0	0	0
RICHARD J LEHMANN
BOARD MEMBER / TREASURER	1.0	X	X	0	0	0
F FRANCIS NAJAFI
BOARD MEMBER	1.0	X		0	0	0
WILLION J POST
BOARD MEMBER	1.0	X		0	0	0
TROY RICHARDS
BOARD MEMBER	1.0	X		0	0	0
THE HONORABLE SKIP RIMSZA
BOARD MEMBER	1.0	X		0	0	0
RAY THURSTON
BOARD MEMBER	1.0	X		0	0	0
HOWARD YOUNG
BOARD MEMBER	1.0	X		0	0	0
TESS BURLESON
BOARD MEMBER	1.0	X		0	438463	21555
JEFFREY M TRENT PHD
BOARD MEMBER	2.0	X		0	1043405	303030
DENISE MCCLINTIC
ASSOCIATE VICE PRESIDENT	40.0			0	167160	7878	X

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	0	TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs	2085676	TotalReportableCompFrmRltdOrgs
Total Other Compensation	361586	TotalOtherCompensation
Number Individuals GT100 K	0	NumberIndividualsGT100K
Formers Listed	false	FormersListed
Total Comp GT150 K	true	TotalCompGT150K
Compensation From Other Sources	false	CompensationFromOtherSources
Number Of Contractors GT100 K	0	NumberOfContractorsGT100K
All Other Contributions	5881499	AllOtherContributions
Total Contributions	5881499	TotalContributions
Total Program Service Revenue	0	TotalProgramServiceRevenue

Investment Income InvestmentIncome

Field	Value	IRS element (for citing)
Total Revenue Column	142156	TotalRevenueColumn
Exclusion	$142,156	ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Gain Or Loss Investments NetGainOrLossInvestments

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Income From Gaming NetIncomeFromGaming

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Income Or Loss NetIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Other Revenue Misc OtherRevenueMisc

Field	Value	IRS element (for citing)
Description	ALL OTHER REVENUE	Description
Business Code	900099	BusinessCode
Total Revenue Column	2063	TotalRevenueColumn
Exclusion	$2,063	ExclusionAmount

Field	Value	IRS element (for citing)
Total Other Revenue	2063	TotalOtherRevenue

Total Revenue TotalRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	6025718	TotalRevenueColumn
Related Or Exempt Function Income	0	RelatedOrExemptFunctionIncome
Unrelated Business Revenue	0	UnrelatedBusinessRevenue
Exclusion	$144,219	ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

Field	Value	IRS element (for citing)
Total	6629446	Total
Program Services	6629446	ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices

Foreign Grants ForeignGrants

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices

Benefits To Members BenefitsToMembers

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices

Comp Current Officers Directors CompCurrentOfficersDirectors

Field	Value	IRS element (for citing)
Total	603808	Total
Program Services	0	ProgramServices
Management And General	60381	ManagementAndGeneral
Fundraising	543427	Fundraising

Comp Disqual Persons CompDisqualPersons

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Other Salaries And Wages OtherSalariesAndWages

Field	Value	IRS element (for citing)
Total	275739	Total
Program Services	0	ProgramServices
Management And General	27574	ManagementAndGeneral
Fundraising	248165	Fundraising

Pension Plan Contributions PensionPlanContributions

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Other Employee Benefits OtherEmployeeBenefits

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Payroll Taxes PayrollTaxes

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Fees For Services Management FeesForServicesManagement

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Fees For Services Legal FeesForServicesLegal

Field	Value	IRS element (for citing)
Total	2693	Total
Program Services	0	ProgramServices
Management And General	2693	ManagementAndGeneral
Fundraising	0	Fundraising

Fees For Services Accounting FeesForServicesAccounting

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Fees For Services Lobbying FeesForServicesLobbying

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	0	Total
Fundraising	0	Fundraising

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Fees For Services Other FeesForServicesOther

Field	Value	IRS element (for citing)
Total	126107	Total
Program Services	0	ProgramServices
Management And General	126107	ManagementAndGeneral
Fundraising	0	Fundraising

Advertising Advertising

Field	Value	IRS element (for citing)
Total	42935	Total
Program Services	0	ProgramServices
Management And General	4293	ManagementAndGeneral
Fundraising	38642	Fundraising

Office Expenses OfficeExpenses

Field	Value	IRS element (for citing)
Total	133827	Total
Program Services	0	ProgramServices
Management And General	13383	ManagementAndGeneral
Fundraising	120444	Fundraising

Information Technology InformationTechnology

Field	Value	IRS element (for citing)
Total	10128	Total
Program Services	0	ProgramServices
Management And General	1013	ManagementAndGeneral
Fundraising	9115	Fundraising

Royalties Royalties

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Occupancy Occupancy

Field	Value	IRS element (for citing)
Total	75694	Total
Program Services	0	ProgramServices
Management And General	7569	ManagementAndGeneral
Fundraising	68125	Fundraising

Travel Travel

Field	Value	IRS element (for citing)
Total	40268	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	40268	Fundraising

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Conferences Meetings ConferencesMeetings

Field	Value	IRS element (for citing)
Total	89278	Total
Program Services	0	ProgramServices
Management And General	8928	ManagementAndGeneral
Fundraising	80350	Fundraising

Interest Interest

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Payments To Affiliates PaymentsToAffiliates

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Depreciation Depletion DepreciationDepletion

Field	Value	IRS element (for citing)
Total	5525	Total
Program Services	0	ProgramServices
Management And General	5525	ManagementAndGeneral
Fundraising	0	Fundraising

Insurance Insurance

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices
Management And General	0	ManagementAndGeneral
Fundraising	0	Fundraising

Other Expenses OtherExpenses (4 entries)

DescriptionDescription	TotalTotal	Management And GeneralManagementAndGeneral	FundraisingFundraising
RECRUITMENT	17625	17625	0
DUES AND SUBSCRIPTIONS	2817	2817	0
SEMINARS & EDUCATION	2550	255	2295
ALL OTHER EXPENSES	37803	37803	0

Total Functional Expenses TotalFunctionalExpenses

Field	Value	IRS element (for citing)
Total	8096243	Total
Program Services	6629446	ProgramServices
Management And General	315966	ManagementAndGeneral
Fundraising	1150831	Fundraising

Cash Non Interest Bearing CashNonInterestBearing

Field	Value	IRS element (for citing)
BOY	3164527	BOY
EOY	254533	EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

Field	Value	IRS element (for citing)
BOY	1734742	BOY
EOY	6186490	EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

Field	Value	IRS element (for citing)
BOY	5353165	BOY
EOY	3398177	EOY

Accounts Receivable AccountsReceivable

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	-1160	EOY

Inventories For Sale Or Use InventoriesForSaleOrUse

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	5548	EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

Field	Value	IRS element (for citing)
BOY	8966	BOY
EOY	25252	EOY

Field	Value	IRS element (for citing)
Land Buildings Equipment Basis	168169	LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec	161826	LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

Field	Value	IRS element (for citing)
BOY	11868	BOY
EOY	6343	EOY

Investments Other Securities InvestmentsOtherSecurities

Field	Value	IRS element (for citing)
BOY	70684	BOY
EOY	0	EOY

Other Assets Total OtherAssetsTotal

Field	Value	IRS element (for citing)
BOY	7165	BOY
EOY	33844	EOY

Total Assets TotalAssets

Field	Value	IRS element (for citing)
BOY	10351117	BOY
EOY	9909027	EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

Field	Value	IRS element (for citing)
BOY	47434	BOY
EOY	1854443	EOY

Deferred Revenue DeferredRevenue

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	443413	EOY

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
BOY	621987	BOY
EOY	0	EOY

Total Liabilities TotalLiabilities

Field	Value	IRS element (for citing)
BOY	669421	BOY
EOY	2297856	EOY

Field	Value	IRS element (for citing)
Follow SFAS117	X	FollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	134667	BOY
EOY	-872677	EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	9484936	BOY
EOY	8421755	EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	62093	BOY
EOY	62093	EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	9681696	BOY
EOY	7611171	EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	10351117	BOY
EOY	9909027	EOY

Field	Value	IRS element (for citing)
Reconcilation Revenue Expenses	-2070525	ReconcilationRevenueExpenses
Reconcilation Other Changes	0	ReconcilationOtherChanges
Method Of Accounting Accrual	X	MethodOfAccountingAccrual
Accountant Compile Or Review	false	AccountantCompileOrReview
FS Audited	true	FSAudited
Audit Committee	true	AuditCommittee
Financial Statement Consolidated	X	FinancialStatementConsolidated
Federal Grant Audit Required	false	FederalGrantAuditRequired

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Publicly Supported Org170b1 Avi	X	PubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	4804855	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	5598863	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	4359865	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	721605	CurrentTaxYearMinus1Year
Current Tax Year	5945925	CurrentTaxYear
Total	21431113	Total

Total170 Total170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	4804855	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	5598863	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	4359865	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	721605	CurrentTaxYearMinus1Year
Current Tax Year	5945925	CurrentTaxYear
Total	21431113	Total

Field	Value	IRS element (for citing)
Amounts Subst Contributors Total	5913570	AmountsSubstContributorsTotal
Public Support Total170	15517543	PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	250673	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	188867	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	74077	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	33934	CurrentTaxYearMinus1Year
Current Tax Year	152708	CurrentTaxYear
Total	700259	Total

Other Income170 OtherIncome170

Field	Value	IRS element (for citing)
Current Tax Year	2334	CurrentTaxYear
Total	2334	Total

Field	Value	IRS element (for citing)
Total Support	22133706	TotalSupport
Public Support Pertcentage170	0.70108	PublicSupportPertcentage170
Public Support Pertcent Prior Year	0.60752	PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170	X	ThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

Field	Value	IRS element (for citing)
Contributor Number	RESTRICTED	ContributorNumber

Contributor Name Business ContributorNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor Address US ContributorAddressUS

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Aggregate Contributions	RESTRICTED	AggregateContributions

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amts		ArtPublicExhibitionAmts
Held Works Of Art Amts		HeldWorksOfArtAmts

Current Year CurrentYear

Field	Value	IRS element (for citing)
Beginning Of Year Balance	62093	BeginningOfYearBalance
Investment Earnings Or Losses	6025	InvestmentEarningsOrLosses
Other Expenditures	6025	OtherExpenditures
End Of Year Balance	62093	EndOfYearBalance

Current Year Minus1 Year CurrentYearMinus1Year

Field	Value	IRS element (for citing)
Beginning Of Year Balance	62093	BeginningOfYearBalance
Investment Earnings Or Losses	7353	InvestmentEarningsOrLosses
Other Expenditures	7353	OtherExpenditures
End Of Year Balance	62093	EndOfYearBalance

Current Year Minus2 Years CurrentYearMinus2Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	62093	BeginningOfYearBalance
Investment Earnings Or Losses	6606	InvestmentEarningsOrLosses
Other Expenditures	6606	OtherExpenditures
End Of Year Balance	62093	EndOfYearBalance

Field	Value	IRS element (for citing)
Board Designated EOY Balance	0.00000	BoardDesignatedEOYBalance
Permanent Endowment EOY Balance	1.00000	PermanentEndowmentEOYBalance
Term Endowment EOY Balance	0.00000	TermEndowmentEOYBalance
Endowments Held By Unrelated Orgs	false	EndowmentsHeldByUnrelatedOrgs
Endowments Held By Related Orgs	true	EndowmentsHeldByRelatedOrgs
Are Related Orgs Listed Schedule R	true	AreRelatedOrgsListedScheduleR
Land		Land
Buildings		Buildings

Leasehold Improvements LeaseholdImprovements

Field	Value	IRS element (for citing)
Investment Cost Or Other Basis	0	InvestmentCostOrOtherBasis
Other Cost Or Other Basis	11053	OtherCostOrOtherBasis
Depreciation	11053	Depreciation
Book Value	0	BookValue

Equipment Equipment

Field	Value	IRS element (for citing)
Investment Cost Or Other Basis	0	InvestmentCostOrOtherBasis
Other Cost Or Other Basis	157116	OtherCostOrOtherBasis
Depreciation	150773	Depreciation
Book Value	6343	BookValue

Other Land Buildings OtherLandBuildings

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	0	OtherCostOrOtherBasis
Depreciation	0	Depreciation
Book Value	0	BookValue

Field	Value	IRS element (for citing)
Total Of Book Value Land Buildings	6343	TotalOfBookValueLandBuildings
Federal Income Tax Liability	0	FederalIncomeTaxLiability
Total Of Amounts	0	TotalOfAmounts

Form990 Schedule D Part XIV Form990ScheduleDPartXIV (2 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
ENDOWMENTS	SCHEDULE D, PART V	THE INSTITUTE'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A SPECIFIC NUMBER OF SUMMER INTERNS EACH YEAR FOR THE NEXT 25 YEARS. THE INSTITUTE CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. THE INSTITUTE CLASSIFIES AS PERMANENTLY RESTRICTED NET ASSETS (1) THE ORIGINAL VALUE OF THE GIFT DONATED TO THE PERMANENT ENDOWMENT, (2) THE ORIGINAL VALUE OF SUBSEQUENT GIFTS TO THE PERMANENT ENDOWMENT, AND (3) ACCUMULATIONS TO THE PERMANENT ENDOWMENT MADE IN ACCORDANCE WITH THE DIRECTION OF THE APPLICABLE DONOR GIFT INSTRUMENT. TGEN FOUNDATION HAS A RESTRICTED ASSET WHICH ALLOWS THEM TO USE ANY INVESTMENT INCOME FOR OPERATING EXPENSES.
ASC 740 (FIN 48) FOOTNOTE	SCHEDULE D, PART X	Management is of the opinion that substantially all of TGens and the Foundations activities are related to their exempt purposes, and no material uncertain tax positions have been identified or recorded in the consolidated financial statements at November 30, 2011 or 2010. TGen and the Foundation file Forms 990 in the U.S. federal jurisdiction and comparable forms in the state of Arizona. The Institute is subject to income tax examinations for 2008 through 2011 in major tax jurisdictions.

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Records Maintained	true	RecordsMaintained

Recipient Table RecipientTable

Recipient Name Business RecipientNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	BusinessNameLine1

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	445 N 5TH STREET STE 600	AddressLine1
City	PHOENIX	City
State	AZ	State
ZIP Code	85004	ZIPCode

Field	Value	IRS element (for citing)
EIN Of Recipient	753065445	EINOfRecipient
IRC Section	501(C)(3)	IRCSection
Amount Of Cash Grant	6629446	AmountOfCashGrant
Amount Of Non Cash Assistance	0	AmountOfNonCashAssistance
Method Of Valuation	N/A	MethodOfValuation
Description Of Non Cash Assistance	N/A	DescriptionOfNonCashAssistance
Purpose Of Grant	FUNDRAISING FOR TGEN	PurposeOfGrant

Field	Value	IRS element (for citing)
Total Nbr Of501 C3 And Govt Grants	1	TotalNbrOf501C3AndGovtGrants
Total Nbr Of Other Organizations	0	TotalNbrOfOtherOrganizations

Form990 Schedule I Part IV Form990ScheduleIPartIV

Field	Value	IRS element (for citing)
Identifier	PROCESS FOR MONITORING USE OF GRANT FUNDS IN THE U.S.	Identifier
Return Reference	SCHEDULE I, PART I, LINE 2	ReturnReference
Explanation	THE FOUNDATION IS ORGANIZED EXCLUSIVELY TO BENEFIT TGEN, A RELATED 501(C)(3) TAX-EXEMPT ORGANIZATION, BY SUPPORTING TGEN'S FUNDRAISING AND DEVELOPMENT FUNCTIONS.	Explanation

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
First Class Or Charter Travel	X	FirstClassOrCharterTravel
Written Policy Re T And E Expenses	true	WrittenPolicyReTAndEExpenses
Substantiation Required	true	SubstantiationRequired
Compensation Committee	X	CompensationCommittee
Independent Consultant	X	IndependentConsultant
Compensation Survey	X	CompensationSurvey
Board Or Committee Approval	X	BoardOrCommitteeApproval
Severance Payment	false	SeverancePayment
Supplemental Nonqual Retire Plan	false	SupplementalNonqualRetirePlan
Equity Based Comp Arrangement	false	EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org	false	CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs	false	CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org	false	CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs	false	CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments	true	AnyNonFixedPayments
Initial Contract Exception	false	InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (4 entries)

Base Compensation Filing OrgBaseCompensationFilingOrg	Comp Based On Related OrgsCompBasedOnRelatedOrgs	Bonus Filing OrgBonusFilingOrg	Bonus Related OrgsBonusRelatedOrgs	Other Compensation Filing OrgOtherCompensationFilingOrg	Other Compensation Related OrgsOtherCompensationRelatedOrgs	Deferred Comp Filing OrgDeferredCompFilingOrg	Deferred Comp Related OrgsDeferredCompRelatedOrgs	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg	Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs	Total Compensation Filing OrgTotalCompensationFilingOrg	Total Compensation Related OrgsTotalCompensationRelatedOrgs	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg	Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
MICHAEL BASSOFF
0	421993	0	0	0	14655	0	22000	0	7123	0	465771	0	0
DENISE MCCLINTIC
0	164155	0	0	0	3005	0	3757	0	4121	0	175038	0	0
TESS BURLESON
0	373106	0	55605	0	9752	0	16500	0	5055	0	460018	0	0
JEFFREY M TRENT PHD
0	853335	0	130000	0	60070	0	291278	0	11752	0	1346435	0	0

Form990 Schedule J Part III Form990ScheduleJPartIII (3 entries)

IdentifierIdentifier	ExplanationExplanation
SCHEDULE J, PART I, LINE 1A	FIRST CLASS TRAVEL IS PERMITTED BY EXECUTIVE STAFF ONLY AND MUST, PER TGEN POLICY, BE PRE-APPROVED BY THE CHIEF OPERATING OFFICER. THESE EXPENSES WERE NOT CONSIDERED AS TAXABLE INCOME TO THE RECIPIENT SINCE THEY WERE REIMBURSEMENTS FOR BUSINESS USE UNDER AN ACCOUNTABLE PLAN.
SCHEDULE J, PART I, LINE 7	SOME OF THE PERSONS LISTED IN FORM 990, PART VII WERE PAID BONUSES WHICH WERE BASED ON ACCOMPLISHMENTS OF SPECIFIC MILESTONES AND/OR PERFORMANCE BASES.
SCHEDULE J, PART II	DR. TRENT IS PAID BY VARI, A RELATED TAX-EXEMPT ORGANIZATION. A PORTION OF HIS SALARY IS THEN REIMBURSED BY TGEN FOR SERVICES RENDERED TO TGEN.

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (16 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
DESCRIPTION OF PROGRAM SERVICE ACCOMPLISHMENTS	FORM 990, PART III, LINE 4	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION ("TGEN FOUNDATION") RAISES FUNDS FOR THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE ("TGEN"). THE PROGRAM SERVICE ACCOMPLISHMENTS OF TGEN ARE LISTED BELOW:
INTRODUCTION		FY11 WAS A YEAR OF ACCELERATED TRANSITION FOR TGEN; ONE THAT LED TO INCREASED OPPORTUNITY TO ADVANCE OUR SCIENCE, BROADEN OUR AUDIENCE, AND - MOST IMPORTANTLY - MAKE A DIFFERENCE FOR PATIENTS. A MAJOR TECHNOLOGY SHIFT AND ONE THAT INFORMED OUR RESEARCH WITH A DEPTH AND PRECISION PREVIOUSLY UNAVAILABLE WAS OUR INCREASED USE OF WHOLE-GENOME SEQUENCING (WGS). WGS PROVIDES THE MOST COMPLETE SET OF COMPARISONS BETWEEN A PATIENT'S NORMAL DNA AND THAT FOUND IN A PATIENT'S CANCEROUS TUMORS. THOUGH IN ITS EARLY STAGES, THE USE OF WGS AS A DIAGNOSTIC AND, IN FACT, A THERAPEUTIC AID TO THE PHYSICIAN'S "TOOLKIT," IS PART OF THE FUTURE IN MEDICINE HAPPENING AT TGEN TODAY. THIS IS TECHNOLOGY THAT CAN REALLY MAKE A DIFFERENCE IN PATIENTS WITH CANCER AND, HOPEFULLY SOON, BEYOND. AFTER HELPING IDENTIFY THE SOURCE OF LAST YEAR'S CHOLERA OUTBREAK IN EARTHQUAKE-RAVAGED HAITI, DR. PAUL KEIM, DIRECTOR OF TGEN'S PATHOGEN GENOMICS DIVISION IN FLAGSTAFF, MET WITH INTERNATIONAL HEALTH OFFICIALS ABOUT HOW TESTS DEVELOPED BY TGEN COULD HELP PREVENT INTERNATIONAL DISEASE OUTBREAKS. TGEN PASSED A MILESTONE IN MAY 2011 WHEN WE LICENSED OUR FIRST DRUG, ONCO-101, A UNIQUE COMPOUND THAT TARGETS CANCER TUMORS BY MODIFYING THE ACTIONS OF PROTEINS. THIS WAS ANOTHER FULFILLMENT TOWARD OUR PRIMARY MISSION OF MOVING LABORATORY DISCOVERIES MORE RAPIDLY INTO THERAPEUTICS FOR PATIENT BENEFIT. CLINICALLY, WE CONTINUE TO LAUNCH INNOVATIVE PROGRAMS THAT EXPAND THE BOUNDARIES OF SCIENCE AND MEDICINE. IN FEBRUARY 2011, COLLABORATING WITH MAYO CLINIC ARIZONA, TGEN FACULTY PERFORMED WHAT WE BELIEVE TO BE THE FIRST WHOLE-GENOME SEQUENCING OF A PATIENT IN AN ACTIVE CLINICAL TRIAL. SEQUENCING PROVIDED A MACRO COMPARISON BETWEEN THE PATIENT'S NORMAL DNA AND THAT OF HIS CANCEROUS TUMOR IN HOPE OF SINGLING OUT AN INDIVIDUAL PROTEIN OR MOLECULAR DRUG TARGET FOR THERAPY. MAYO CLINICIANS USED THE RESULTS TO INFORM THEIR CHOICE OF HOW TO BEST TREAT THE PATIENT. THIS GENOMIC-BASED PERSONALIZED MEDICINE APPROACH MAY SOON BECOME THE STANDARD THERAPEUTIC BAROMETER. FUNDS FROM A FLINN FOUNDATION PROTEOMICS GRANT PROVIDE SIGNIFICANT SUPPORT FOR THE DEVELOPMENT OF A COMPREHENSIVE AND SUSTAINABLE PROGRAM IN PROTEOMIC SCIENCES AT TGEN AND ENABLE THE GOALS OF THE PARTNERSHIP FOR PERSONALIZED MEDICINE (PPM). WE ARE COLLABORATING WITH LOCAL RESEARCH AND TECHNOLOGY DEVELOPMENT PARTNERS TO ACCELERATE OUTCOMES THAT REALIZE THE MISSION OF THE PPM: TO DISCOVER AND VALIDATE NEW PROTEIN-BASED BIOMARKERS OF HUMAN DISEASE THAT WILL DIRECTLY INFORM CLINICAL DECISIONS FOR INDIVIDUAL PATIENTS AND IMPROVE HEALTH CARE. WE ALSO CONTINUE TO BENCHMARK A NUMBER OF ADMINISTRATIVE FUNCTIONS TO FURTHER REFINE AND DEVELOP OUR EFFORTS IN SUPPORT OF SCIENCE. CORE AREAS INCLUDE BUSINESS DEVELOPMENT, CONTRACTS, GRANTS AND PROJECT MANAGEMENT. THIS COMMITMENT TO CONTINUOUS IMPROVEMENT ALLOWS TGEN TO OPERATE AT ITS HIGHEST LEVEL. PEER-REVIEWED LABORATORY RESEARCH, PUBLICATIONS, AND PRESENTATIONS SINCE ITS INCEPTION, THE RESEARCH AND CLINICAL ASPECTS OF TGEN HAVE FOCUSED SOLELY ON THE PATIENT AS THE END POINT. OUR CLINICAL TRIALS - IN COLLABORATION WITH SCOTTSDALE HEALTHCARE, MAYO CLINIC AND OTHERS - NOT ONLY OFFER HOPE TO PATIENTS SUFFERING FROM MANY TYPES OF CANCER, THE RESULTS SERVE TO INFORM OUR RESEARCH STUDIES. SUPPORTED BY A NEW WAVE OF TECHNOLOGY, TGEN'S RESEARCH AND CLINICAL EFFORTS REMAIN EQUAL TO THE STRENGTHS AND CAPABILITIES OF ANY OF TODAY'S LEADING RESEARCH AND CLINICAL INSTITUTES AND IN FY11 HELPED LAND THREE MAJOR INITIATIVES. 1. AS PART OF A STAND UP TO CANCER MELANOMA DREAM TEAM, TGEN AND THE BARBARA ANN KARMANOS CANCER INSTITUTE WILL LEAD A $6 MILLION NATIONAL AND INTERNATIONAL STUDY OF A DEADLY TYPE OF SKIN CANCER, BRAF WILD-TYPE, FOR WHICH THERE ARE FEW TREATMENT OPTIONS. TGEN PREVIOUSLY RECEIVED A SU2C GRANT FOR PANCREATIC CANCER RESEARCH. 2. DELL ANNOUNCED A MAJOR COMMITMENT OF FUNDING, EMPLOYEE ENGAGEMENT AND CLOUD COMPUTING TECHNOLOGY TO SUPPORT PEDIATRIC CANCER RESEARCH PROGRAMS GLOBALLY, INCLUDING THE WORLD'S FIRST PERSONALIZED MEDICINE TRIAL FOR PEDIATRIC CANCER CONDUCTED BY THE NEUROBLASTOMA AND MEDULLOBLASTOMA TRANSLATIONAL RESEARCH CONSORTIUM (NMTRC), SUPPORTED BY TGEN. WE WILL USE OUR GENOMIC TECHNOLOGY WITHIN DELL'S DONATED CLOUD TO HELP NMTRC IDENTIFY A GREATER DEPTH OF PERSONALIZED TREATMENT STRATEGIES FOR CHILDREN WITH NEUROBLASTOMA ENROLLED IN NMTRC'S CLINICAL TRIAL. 3. TGEN BECAME PART OF A TEAM OF MEDICAL INVESTIGATORS WHO RECEIVED A $3.5 MILLION PROMISE GRANT FROM SUSAN G. KOMEN FOR THE CURE TO STUDY TRIPLE-NEGATIVE BREAST CANCER, ANOTHER TYPE OF CANCER FOR WHICH THERE NOW ARE FEW TREATMENT OPTIONS. AREAS OF RESEARCH FALL INTO THREE CATEGORIES - ONCOLOGY (MELANOMA, BREAST, PROSTATE, OVARIAN, LUNG CANCERS, ETC.), METABOLIC DISEASES (DIABETES AND HEART DISEASE) AND NEUROLOGICAL DISEASES (AUTISM, ALZHEIMER'S, ALS, AND OTHER BRAIN-RELATED DISEASES) - ALL OF WHICH IMPACT ARIZONANS AT ALARMING RATES. THE RESEARCH RESULTS APPEAR IN A NUMBER OF SCIENTIFIC AND MEDICAL JOURNALS AND ADD TO THE GROWING KNOWLEDGE BASE OF MOLECULAR RESEARCH AND MEDICINE. IN FY11, TGEN RESEARCHERS PUBLISHED THEIR RESEARCH RESULTS IN NUMEROUS SCHOLARLY PEER-REVIEWED ACADEMIC JOURNALS AND THROUGH PRESENTATIONS AT LEADING NATIONAL AND INTERNATIONAL CONFERENCES. THESE INCLUDE PUBLICATION IN LEADING SCIENTIFIC JOURNALS SUCH AS NATURE, CANCER, JOURNAL OF CLINICAL ONCOLOGY, PLOS, MOLECULAR CANCER RESEARCH, AND A HOST OF OTHER DISEASE-ASSOCIATED PUBLICATIONS (E.G. DIABETES, JOURNAL OF CANCER, ETC).
SELECT HIGHLIGHTS FOR FY11		1. IN A STUDY OF 144 PATIENTS WITH ADVANCED CANCER, INCLUDING COLORECTAL, OTHER GASTROINTESTINAL AND PROSTATE CANCERS, RESEARCHERS AT TGEN AND SCOTTSDALE HEALTHCARE DOCUMENTED A STATISTICALLY SIGNIFICANT DECREASE IN PROGRESSION-FREE SURVIVAL WITH EACH SUCCESSIVE STANDARD THERAPY. THE STUDY PUBLISHED NOV. 28 IN THE JOURNAL OF CANCER CONCLUDED THAT NEW THERAPIES THAT REVERSE THIS TREND MIGHT LEAD TO IMPROVED CLINICAL OUTCOMES. CITATION: "PROGRESSION-FREE SURVIVAL DECREASES WITH EACH SUBSEQUENT THERAPY IN PATIENTS PRESENTING FOR PHASE I CLINICAL TRIALS." CHRISTOPHER H. BAILEY, GAYLE JAMESON, CHAO SIMA, SHARON FLECK, ERICA WHITE, DANIEL D. VON HOFF, GLEN J. WEISS. J CANCER 2012; 3:7-13. 2. A TGEN STUDY PUBLISHED NOV. 22 IN THE JOURNAL OF LUNG CANCER SHOWED THAT KEY DOWNSTREAM COMPONENTS OF THE HEDGEHOG SIGNALING PATHWAY (HHSP), WHICH HAS BEEN IMPLICATED IN THE DEVELOPMENT OF MULTIPLE CANCERS, SHOW CORRELATION WITH SONIC HEDGEHOG LIGAND (SHH) EXPRESSION, SUGGESTING THAT LIGAND-DEPENDENT SIGNALING IS MORE PREVALENT IN PRIMARY NON-SMALL CELL LUNG CANCER TUMORS. CITATION: RAZ G, ALLEN KE, KINGSLEY C, CHERNI I, ARORA S, WATANABE A, LORENZO CD, EDWARDS V DK, SRIDHARS, HOSTETTER G, WEISS GJ. "HEDGEHOG SIGNALING PATHWAY MOLECULES AND ALDH1A1 EXPRESSION IN EARLY-STAGE NON-SMALL CELL LUNG CANCER." DOI:10.1016/J.LUNGCAN.2011.10.015. 3. TGEN AND SCOTTSDALE HEALTHCARE COLLABORATORS AT THE VIRGINIA G. PIPER CANCER CENTER DISCOVERED A BETTER TREATMENT FOR PANCREATIC CANCER PATIENTS, ACCORDING TO A STUDY PUBLISHED IN THE PAST MONTH BY THE JOURNAL OF CLINICAL ONCOLOGY. THIS SIGNIFICANT STUDY SHOWED THAT A COMBINATION OF DRUGS HELPED EXTEND SURVIVAL OF PANCREATIC CANCER PATIENTS, PRODUCED "SUBSTANTIAL" ANTI-TUMOR ACTIVITY, AND THAT A PHASE III STUDY IS WARRANTED. CITATION: "GEMCITABINE PLUS NAB-PACLITAXEL IS AN ACTIVE REGIMEN IN PATIENTS WITH ADVANCED PANCREATIC CANCER: A PHASE I/II TRIAL." DANIEL D. VON HOFF, RAMESH K. RAMANATHAN, MITESH J. BORAD, DANIEL LAHERU, LON S. SMITH, TINA E. WOOD, RONALD L. KORN, NEIL DESAI, VUONG TRIEU, JOSE L. IGLESIAS, HUI ZHANG, PATRICK SOON-SHIONG, TAO SHI, N.V. RAJESHKUMAR, ANIRBAN MAITRA, AND MANUEL HIDALGO. J CLIN ONCOL 29. 2011 BY AMERICAN SOCIETY OF CLINICAL ONCOLOGY. ZDOI:10.1200/JCO.2011.36.5742. 4. USING WHOLE-GENOME SEQUENCING, TGEN'S PATHOGEN GENOMICS DIVISION PINPOINTED THE SOURCE OF LAST YEAR'S CHOLERA OUTBREAK IN EARTHQUAKE-BATTERED HAITI, ACCORDING TO A STUDY PUBLISHED AUGUST 23 IN THE NEW JOURNAL MBIO. THE RESULTS INDICATED THAT THE SOURCE OF THE INFECTION (CONFIRMED BY MULTIPLE LABORATORIES) WAS THE NEPAL PEACEKEEPING SOLDIERS, WHO UNKNOWINGLY BROUGHT THE DISEASE. DR. KEIM AND HIS TEAM SHOWED CONCLUSIVELY THAT IN THE FUTURE SIMPLE TESTS COULD HELP IDENTIFY QUICKLY THE CAUSATIVE AGENT AND ALLOW RAPID STEPS TO PREVENT SUCH DISEASE OUTBREAKS IN THE WAKE OF FUTURE DISASTERS. CITATION: "POPULATION GENETICS OF VIBRIO CHOLERAE FROM NEPAL IN 2010: EVIDENCE ON THE ORIGIN OF THE HAITIAN OUTBREAK." RENE S. HENDRIKSEN, PAUL S. KEIM, LANCE B. PRICE, DAVID M. ENGELTHALER, ET AL. 2011. MBIO 2(4):E00157-11. DOI:10.1128/MBIO.00157-11. 5. COLLABORATING WITH VAN ANDEL RESEARCH INSTITUTE SCIENTISTS, INCLUDING DR. JEFF MACKEIGAN, TGEN'S DR. GLEN WEISS PRESENTED AN ABSTRACT IN JULY AT THE 14TH WORLD CONFERENCE ON LUNG CANCER IN AMSTERDAM. THE STUDY FOUND THAT THE STAT3 GENE IS ACTIVATED IN SOME NON-SMALL-CELL LUNG CANCER (NSCLC) CELL LINES BY THE JAK2 PROTEIN AND THAT THIS SIGNALING CAN PLAY A CRUCIAL ROLE IN TUMOR-CELL BEHAVIOR THAT MAY NOT BE EFFECTIVELY INHIBITED BY DRUGS THAT SELECTIVELY TARGET THESE MUTATIONS. CITATION: "STAT3 IS ACTIVATED BY JAK2 INDEPENDENT OF KEY ONCOGENIC DRIVER MUTATIONS IN NSCLC." G.J. WEISS, B.D. LOOYENGA, D. HUTCHINGS, I. CHERNI, C. KINGSLEY, C.D. LORENZO, D.K. EDWARDS V, S. SRIDHAR, J.P. MACKEIGAN. ALSO PUBLISHED IN A SUPPLEMENT OF THE JOURNAL OF THORACIC ONCOLOGY. 6. DEADLY BACTERIA MAY BE EVOLVING ANTIBIOTIC RESISTANCE BY MIMICKING HUMAN PROTEINS, ACCORDING TO A TGEN STUDY PUBLISHED MAY 26 IN THE JOURNAL PUBLIC LIBRARY OF SCIENCE (PLOS) ONE. DR. MIA CHAMPION OF TGEN'S PATHOGEN GENOMICS DIVISION SHOWED HOW THIS PROCESS OF "MOLECULAR MIMICRY" MAY HELP EXPLAIN WHY BACTERIAL HUMAN PATHOGENS, MANY OF WHICH WERE AT ONE TIME EASILY TREATABLE WITH ANTIBIOTICS, HAVE RE-EMERGED IN RECENT YEARS AS HIGHLY INFECTIOUS PUBLIC HEALTH THREATS. CITATION: "HOST-PATHOGEN O-METHYLTRANSFERASE SIMILARITY AND ITS SPECIFIC PRESENCE IN HIGHLY VIRULENT STRAINS OF FRANCISELLA TULARENSIS SUGGESTS MOLECULAR MIMICRY." MIA D. CHAMPION. PLOS ONE. 2011; 6(5): E20295. PUBLISHED ONLINE 2011 MAY 26. DOI: 10.1371/JOURNAL.PONE.0020295. 7. A GENE CALLED PVT1 MAY HELP REDUCE THE KIDNEY'S ABILITY TO FILTER BLOOD, LEADING TO KIDNEY DISEASE, KIDNEY FAILURE AND DEATH, ACCORDING TO A STUDY PUBLISHED APRIL 22 IN THE PUBLIC LIBRARY OF SCIENCE (PLOS) ONE. THE TGEN TEAM FOUND PVT1 EXPRESSION LEVELS INCREASED UP TO 5-FOLD IN RESPONSE TO HYPERGLYCEMIA, OR HIGH BLOOD SUGAR, A CONDITION THAT OFTEN ACCOMPANIES DIABETES. CITATION: "FUNCTIONAL CHARACTERIZATION OF THE PLASMACYTOMA VARIANT TRANSLOCATION 1 GENE (PVT1) IN DIABETIC NEPHROPATHY." M. LUCRECIA ALVAREZ AND JOHANNA K. DISTEFANO. PLOS ONE 6(4): E18671. 8. DRUG-RESISTANT STRAINS OF STAPHYLOCOCCUS AUREUS, A BACTERIA LINKED TO A WIDE RANGE OF HUMAN DISEASES, ARE PRESENT IN MEAT AND POULTRY FROM U.S. GROCERY STORES AT UNEXPECTEDLY HIGH RATES, ACCORDING TO A NATIONWIDE TGEN STUDY PUBLISHED APRIL 15 IN THE JOURNAL CLINICAL INFECTIOUS DISEASES. NEARLY HALF OF THE MEAT AND POULTRY SAMPLES - 47 PERCENT - WERE CONTAMINATED WITH S. AUREUS, AND MORE THAN HALF OF THOSE BACTERIA - 52 PERCENT - WERE RESISTANT TO AT LEAST THREE CLASSES OF ANTIBIOTICS. CITATION: "MULTIDRUG-RESISTANT STAPHYLOCOCCUS AUREUS IN U.S. MEAT AND POULTRY." ANDREW E. WATERS, TANIA CONTENTE-CUOMO, JORDAN BUCHHAGEN, CINDY M. LIU, LINDSEY WATSON, KIMBERLY PEARCE, JEFFREY T. FOSTER, JOLENE BOWERS, ELIZABETH M. DRIEBE, DAVID M. ENGELTHALER, PAUL S. KEIM AND LANCE B. PRICE. CLIN INFECT DIS. (2011). 9. PUBLISHED MARCH 24 IN THE PRESTIGIOUS JOURNAL, NATURE, A NATIONWIDE STUDY BY 20 INSTITUTES, INCLUDING TGEN, UNVEILED THE MOST COMPREHENSIVE PICTURE TO DATE OF THE GENETIC BLUEPRINT OF MULTIPLE MYELOMA, AN ALL-TOO-COMMON FORM OF BONE MARROW CANCER. THE STUDY INVOLVED WHOLE GENOME SEQUENCING OF NORMAL AND TUMOR DNA FROM 38 MULTIPLE MYELOMA PATIENTS TO ASSESS TUMOR-SPECIFIC CHANGES ACROSS THE ENTIRE 3-BILLION-LETTER HUMAN GENOME, YIELDING NEW AND UNEXPECTED INSIGHTS INTO THE EVENTS THAT LEAD TO THIS FORM OF CANCER. CITATION: "INITIAL GENOME SEQUENCING AND ANALYSIS OF MULTIPLE MYELOMA." TGEN CONTRIBUTORS WERE: ANGELA BAKER, JOHN CARPTEN AND JEFFREY TRENT. NATURE 471, 467-472 (24 MARCH 2011). 10. A STUDY PUBLISHED IN THE FEBRUARY 2011 EDITION OF MOLECULAR CANCER RESEARCH OUTLINES HOW GENOMIC RESEARCH COULD HELP DOCTORS BETTER TARGET A DRUG, OXALIPLATIN. IT IS WIDELY USED TO TREAT COLORECTAL CANCER PATIENTS, BUT OFTEN HAS SIGNIFICANT SIDE EFFECTS, CREATING AN URGENT NEED TO IDENTIFY PATIENTS MOST LIKELY TO BENEFIT FROM THIS THERAPY. CITATION: "FUNCTIONAL GENOMICS REVEALS DIVERSE CELLULAR PROCESSES THAT MODULATE TUMOR CELL RESPONSE TO OXALIPLATIN." KELLY A HARRADINE, MICHELLE KASSNER, DONALD CHOW, MERAJ AZIZ, DANIEL D. VON HOFF, JOFFRE BAKER, HOLLY YIN AND ROBERT J. PELHAM. MOL CANCER RES; PUBLISHED ONLINEFIRST DECEMBER 17, 2010; DOI:10.1158/1541-7786.MCR-10-0412. 11. CANCER PATIENTS ARE WILLING TO UNDERGO MANY TESTS TO RECEIVE ADVANCED EXPERIMENTAL TREATMENT IN CLINICAL TRIALS, ACCORDING TO A TGEN-LED STUDY PUBLISHED IN JANUARY IN THE JOURNAL CANCER. RESEARCHERS SAID PATIENTS' WILLINGNESS TO UNDERGO TESTS BODES WELL FOR THE FUTURE OF PERSONALIZED MEDICINE, IN WHICH SPECIFIC TREATMENTS ARE PRESCRIBED DEPENDING ON THE DNA GENETIC MAKEUP OF PATIENTS' TUMORS. CITATION: "PATIENT WILLINGNESS TO UNDERGO PHARMACODYNAMIC AND PHARMACOKINETIC TESTS IN EARLY PHASE ONCOLOCY TRIALS." RAOUL TIBES, MD, PHD; BARBARA F. PIPER, DNSC, RN;JESSICA A. SMITH, BA; RAYSENIA L. JAMES, MPH; MARTIN A. BENJAMIN, BS; JAY H. YIM; RAMESH K. RAMANATHAN, MD; DANIEL D. VON HOFF, MD; R. CURTIS BAY, PHD; AND MITESH J. BORAD, M.D. CANCER. 2011 JAN 18.
CLINICAL RESEARCH		ESTABLISHED IN 2006, A STRATEGIC ALLIANCE WITH SCOTTSDALE HEALTHCARE (SHC) PROVIDES A DIRECT CLINICAL RESEARCH SITE FOR TGEN. THE COLLABORATION BRINGS NEW CLINICAL RESEARCH INTO THE COMMUNITY TO THOSE PATIENTS WHO WOULD OTHERWISE HAVE TO TRAVEL SOMEPLACE ELSE FOR ACCESS TO NEW THERAPIES OR PREVENTION AGENTS. IN THE PAST SIX YEARS, THESE CLINICAL TRIALS HAVE PROVIDED OPTIONS THAT DID NOT EXIST BEFORE TO PHOENIX-AREA PATIENTS AS WELL AS PATIENTS FROM ALL OVER THE COUNTRY. TRIALS IN FY11 PROVIDED HOPE FOR PATIENTS WITH ADVANCED AND/OR RARE CANCERS. ELIGIBLE CANCER PATIENTS WHO CONSENT TO PARTICIPATE IN A CLINICAL TRIAL STUDY WILL RECEIVE TREATMENT COORDINATED BY SCOTTSDALE HEALTHCARE. THE TREATMENT TEAM MAY INCLUDE RESEARCH PHYSICIANS, RESEARCH NURSES, DATA MANAGERS AND COMMUNITY ONCOLOGISTS. TGEN PHYSICIAN-IN-CHIEF DANIEL D. VON HOFF, M.D., LEADS THE TRIALS. DR. VON HOFF ALSO SERVES AS CHIEF SCIENTIFIC OFFICER FOR SCOTTSDALE HEALTHCARE RESEARCH INSTITUTE. OTHER MEMBERS OF THE CLINICAL TEAM INCLUDE: RAMESH K. RAMANATHAN, M.D. MEDICAL DIRECTOR, TCRS; DIRECTOR, GASTROINTESTINAL ONCOLOGY PROGRAM GLEN J. WEISS, M.D. DIRECTOR, THORACIC ONCOLOGY PROGRAM JASGIT SACHDEV, M.D. ASSOCIATE INVESTIGATOR GAYLE JAMESON, MSN, ACNP, AOCN DIRECTOR, SUPPORTIVE CARE PROGRAM, ASSISTANT INVESTIGATOR CATHY MAST, APRN-BC, AOCNP NURSE PRACTITIONER JOYCE SCHAFFER, RN, MSN,OCN CANCER CLINICAL TRIALS COORDINATOR PARTICIPANTS IN CLINICAL TRIALS CAN PLAY A MORE ACTIVE ROLE IN THEIR OWN HEALTH CARE, GAIN ACCESS TO NEW RESEARCH TREATMENTS BEFORE THEY ARE WIDELY AVAILABLE, AND HELP OTHERS BY CONTRIBUTING TO MEDICAL RESEARCH. CLINICAL TRIALS ARE CONDUCTED IN PHASES. THE TRIALS AT EACH PHASE HAVE A DIFFERENT PURPOSE AND HELP SCIENTISTS ANSWER DIFFERENT QUESTIONS: IN PHASE I TRIALS, RESEARCHERS TEST AN EXPERIMENTAL DRUG OR TREATMENT IN A SMALL GROUP OF PEOPLE (20-80) FOR THE FIRST TIME TO EVALUATE ITS SAFETY, DETERMINE A SAFE DOSAGE RANGE, AND IDENTIFY SIDE EFFECTS. IN PHASE II TRIALS, THE EXPERIMENTAL STUDY DRUG OR TREATMENT IS GIVEN TO A LARGER GROUP OF PEOPLE (100-300) TO SEE IF IT IS EFFECTIVE AND TO FURTHER EVALUATE ITS SAFETY. IN PHASE III TRIALS, THE EXPERIMENTAL STUDY DRUG OR TREATMENT IS GIVEN TO LARGE GROUPS OF PEOPLE (1,000-3,000) TO CONFIRM ITS EFFECTIVENESS, MONITOR SIDE EFFECTS, COMPARE IT TO COMMONLY USED TREATMENTS, AND COLLECT INFORMATION THAT WILL ALLOW THE EXPERIMENTAL DRUG OR TREATMENT TO BE USED SAFELY. IN PHASE IV TRIALS, POST-MARKETING STUDIES DELINEATE ADDITIONAL INFORMATION INCLUDING THE DRUG'S RISKS, BENEFITS, AND OPTIMAL USE. PATIENT PARTICIPATION IN CLINICAL TRIALS AT TCRS - 300 VISITS PER MONTH - 35-45 NEW PATIENTS PER MONTH - AVERAGE 95 ACTIVE CLINICAL TRIAL PATIENTS
GRANT SUPPORT		GRANT FUNDING IS OFTEN THE LIFEBLOOD OF RESEARCH. IN FY11, TGEN INVESTIGATORS SUBMITTED 145 GRANTS TOTALING $152,705,359. TGEN WAS AWARDED 17 GRANTS, TOTALING $4,189,894, WITH AN ADDITIONAL 56 GRANTS PENDING AND IN REVIEW TOTALING $64,521,876. ADDITIONALLY, TGEN RECEIVED $3,441,653 FROM PREVIOUS FY PENDING GRANTS, BRINGING THE AWARDED TOTAL FOR GRANTS IN FY11 TO $7,631,547. TGEN'S SUCCESS RATE CURRENTLY RESTS AT 24 PERCENT OF TOTAL GRANTS SUBMITTED, PLACING THE INSTITUTE NEARLY FOUR PERCENT HIGHER THAN THE NATIONAL AVERAGE (NIH OVERALL SUCCESS RATE). A FY11 BIOMARKER GRANT ALLOWED TGEN TO ENHANCE OUR SCIENTIFIC INFRASTRUCTURE AND BUILD A COMPLETE BIOMARKER DEVELOPMENT PIPELINE, FROM THE IDENTIFICATION OF APPROPRIATE PATIENT POPULATIONS FOR CLINICAL STUDIES TO THE ACQUISITION, PROCESSING, AND QUALITY CONTROL OF BIOSPECIMENS AND FROM BIOMARKER DISCOVERY TO CLINICAL APPLICATION. BIOMARKERS - OBJECTIVE BIOLOGICAL INDICATORS OF AN INDIVIDUAL'S STATE OF HEALTH OR DISEASE - HAVE THE POTENTIAL TO REVOLUTIONIZE MEDICAL DIAGNOSIS AND PROGNOSIS THROUGH EARLY DISEASE DETECTION, THERAPY MONITORING, AND MATCHING THE RIGHT PATIENT WITH THE RIGHT DRUG, THE HALLMARK OF PERSONALIZED, PRECISION MEDICINE. YET, DESPITE THE MORE THAN 40,000 PUBLICATIONS PURPORTING AN ASSOCIATION OF BIOMARKERS TO SPECIFIC DISEASES AND THE PROMINENT REFERENCE TO BIOMARKER USE IN FDA INITIATIVES TO OVERHAUL OUR HEALTH CARE SYSTEM, THE APPROVAL RATE FOR PROTEIN BIOMARKERS HAS BEEN LOW: FEWER THAN TWO DOZEN BIOMARKERS HAVE BEEN APPROVED BY THE FDA. THE REASONS FOR THE LOW ADOPTION RATE INCLUDE A HIGH FALSE MARKER DISCOVERY RATE, BUT PERHAPS MORE IMPORTANTLY, A LACK OF METHODOLOGIES FOR ANALYZING CANDIDATE BIOMARKERS IN LARGE NUMBERS OF CLINICAL SAMPLES IN A ROBUST, HIGH THROUGHPUT MANNER (SO CALLED BIOMARKER VERIFICATION) THAT MAKES VALIDATION FOR CLINICAL USE POSSIBLE. TGEN IS COMMITTED TO THE REALIZATION OF PERSONALIZED MEDICINE ACKNOWLEDGING THE IMPORTANT CHALLENGES THAT MUST BE MET TO ENSURE ITS SUCCESS. HISTORICALLY, BIOMARKER DEVELOPMENT HAS BEEN HAMPERED BY A LACK OF STANDARDIZED TECHNOLOGIES AND METHODOLOGIES THAT ARE CRITICALLY NEEDED TO MORE EFFECTIVELY DISCOVER AND VALIDATE MARKERS THAT ARE INDICATIVE OF DISEASE CONDITIONS. LIKEWISE, SYSTEMATIC METHODS FOR CONSISTENT BIOSPECIMEN COLLECTION AND PROCESSING AS WELL AS INTEGRATION AND INTERPRETATION OF DATA IN A ROBUST, STATISTICALLY SIGNIFICANT MANNER AMONGST DIFFERENT LABORATORIES ARE DESPERATELY NEEDED TO APPROPRIATELY VALIDATE BIOMARKERS FOR CLINICAL USE. THE INFRASTRUCTURE DEVELOPED AT TGEN SPEAKS DIRECTLY TO THESE GAPS IN THE BIOMARKER DEVELOPMENT PIPELINE. TGEN HAS LEVERAGED FUNDS IN THIS AREA TO DEVELOP A COMPREHENSIVE AND SUSTAINABLE PROGRAM TO ENABLE ALL STAGES OF BIOMARKER DEVELOPMENT FROM DISCOVERY THROUGH VALIDATION. THE GRANT SUPPORTS SEVERAL TGEN-LED COLLABORATIONS WITH RESEARCH AND TECHNOLOGY DEVELOPMENT PARTNERS THROUGHOUT ARIZONA TO ADVANCE UNIQUE PIECES OF THE BIOMARKER DEVELOPMENT PIPELINE INCLUDING: o TGEN ESTABLISHED THE MACROMOLECULAR ANALYSIS AND PROCESSING CENTER, A CENTRALIZED BIOREPOSITORY THAT APPLIES BEST PRACTICES FOR BIOSPECIMEN PROCUREMENT AND DNA, RNA, AND PROTEIN ISOLATION FOR DOWNSTREAM ANALYSIS o ROBOTIC AUTOMATION FOR BIOSPECIMEN PROCESSING - A COLLABORATION WITH DR. DEIDRE MELDRUM'S CENTER FOR BIOSIGNATURES DISCOVERY AUTOMATION AT THE BIODESIGN INSTITUTE AT ASU TO AUTOMATE ALL THE TIME AND LABOR-INTENSIVE STEPS OF BIOSPECIMEN PROCESSING TO LIMIT SAMPLE TO SAMPLE VARIABILITY FOR LARGE-SCALE BIOMARKER VALIDATION STUDIES o DATA ANALYSIS AND INFORMATION MANAGEMENT - TGEN HAS DEVELOPED OR PURCHASED REQUISITE SYSTEMS TO STREAMLINE DATA ACQUISITION, ANALYSIS, AND STORAGE FOR GENOMIC AND PROTEOMIC STUDIES. THIS ANALYSIS INFRASTRUCTURE SUPPORTED BY THE FLINN FOUNDATION GRANT HAS BEEN LEVERAGED BY SEVERAL OF TGEN'S PERSONALIZED MEDICINE STUDIES, INCLUDING ONE THAT ATTEMPTS TO IDENTIFY GENOMIC AND PROTEOMIC BIOMARKERS THAT PREDICT WHICH CHEMOTHERAPY WILL BE MOST EFFECTIVE IN THE TREATMENT OF INDIVIDUAL PATIENTS WITH LUNG CANCER. IN TOTAL, FLINN SUPPORT HAS ALLOWED TGEN TO ENHANCE OUR SCIENTIFIC INFRASTRUCTURE AND BUILD A COMPLETE BIOMARKER DEVELOPMENT PIPELINE, FROM THE IDENTIFICATION OF APPROPRIATE PATIENT POPULATIONS FOR CLINICAL STUDIES TO THE ACQUISITION, PROCESSING, AND QUALITY CONTROL OF BIOSPECIMENS AND FROM BIOMARKER DISCOVERY TO CLINICAL APPLICATION. THE PROTEOMICS PIPELINE SUPPORTS THE INITIAL GOALS OF OUR FIRST PARTNERSHIP FOR PERSONALIZED MEDICINE DEMONSTRATION PROJECT IN LUNG CANCER, BUT MORE IMPORTANTLY, DEVELOPS THE REQUIRED INFRASTRUCTURE TO POSITION TGEN FAVORABLY FOR ATTRACTING ADDITIONAL PARTNERS TO DEVELOP DIAGNOSTIC BIOMARKERS FOR A MULTITUDE OF HUMAN DISEASES.
FY11 HIGHLIGHTS		1. TWO-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) TOTALING $3 MILLION TO DR. JOHANNA DISTEFANO TO STUDY THE PROGRESSION AND GENETIC ORIGINS OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD). 2. TWO-YEAR GRANT FROM THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) TOTALING $672,000 TO DR. JOHN CARPTEN FOR WHOLE-TRANSCRIPTOME RNA SEQUENCING OF MULTIPLE MYELOMA TUMORS USING NEXT-GENERATION TECHNOLOGY. 3. TWO-YEAR GRANT FROM THE MMRF TOTALING $250,000 TO DR. JONATHAN KEATS FOR A STUDY OF THE CONSEQUENCES OF LOSING THE GENE KDMSA/UTX, A TUMOR SUPPRESSOR IN MULTIPLE MYELOMA. 4. TWO-YEAR GRANT FROM THE MMRF TOTALING $249,999 TO DR. JONATHAN KEATS TO CHARACTERIZE COMMERCIAL MYELOMA CELL LINES. 5. THREE-YEAR GRANT FROM ARIZONA BIOMEDICAL RESEARCH COMMISSION TOTALING $218,000 TO DR. HAIYONG HAN TO EVALUATE COMPOUNDS IN CELL LINES TO VALIDATE THEIR ANTI-TUMOR POTENTIAL. 6. ONE-YEAR GRANT FROM NIH TOTALING $139,500 TO DR. HOLLY YIN AND DR. NATHALIE MEURICE TO DEVELOP TESTS FOR GENES RELATED TO SUBSTANCE ABUSE, ESPECIALLY TOBACCO SMOKING, AS WELL AS PARKINSON'S DISEASE. 7. FIVE-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TOTALING $775,899 TO DR. DAVID CRAIG TO INVESTIGATE PHARMACOGENOMICS OF MOOD STABILIZER RESPONSE IN BIPOLAR DISORDER. 8. FOUR-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TOTALING $457,976 TO DR. JOHN CARPTEN TO STUDY GENETIC RISK FACTORS IN AFRICAN AMERICAN COLORECTAL CANCER PATIENTS. 9. TWO-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TOTALING $184,881 TO DR. JOHANNA DISTEFANO TO STUDY THE GENETIC DETERMINANTS OF TOTAL CHOLESTEROL LEVELS IN AMERICAN INDIANS. 10. FIVE-YEAR GRANT FROM THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES TOTALING $1.7 MILLION TO DR. MICHAEL BITTNER TO SUPPORT THE DEVELOPMENT OF A GENE EXPRESSION-BASED BIODOSIMETER TO MEASURE RADIATION. 11. TWO-YEAR GRANT FROM THE U.S. DEPARTMENT OF HOMELAND SECURITY TOTALING $1.1 MILLION TO DR. PAUL KEIM TO STUDY HOW NEXT-GENERATION SEQUENCING TECHNIQUES COULD HELP DETECT RARE VARIANTS IN BACILLUS ANTHRACIS (ANTHRAX) CULTURES. 12. TWO-YEAR GRANT FROM THE U.S. DEPARTMENT OF DEFENSE TOTALING $1 MILLION TO DR. LANCE PRICE TO INVESTIGATE - IN COLLABORATION WITH THE ARIZONA BURN CENTER - NOVEL TOOLS AND ANALYSIS TO MOLECULARLY CHARACTERIZE BURN WOUND MICROBIAL COLONIZATION AND THEIR EFFECTS ON HEALING, GRAFT REJECTION AND INFECTION. 13. ONE-YEAR GRANT FROM THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES TOTALING $297,000 TO PURCHASE NEXT GENERATION SEQUENCING EQUIPMENT. 14. TWO-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TOTALING $117,000 STUDY BACTERIAL AND FUNGAL ECOLOGY IN THE CHRONIC RHINSINUSITIS MICROBIOME AS PART OF THE HUMAN MICROBIOME PROJECT, WHICH SEEKS TO ASSESS THE ASSOCIATIONS BETWEEN MICROBIOTA AND HUMAN HEALTH AND DISEASE. ENTERPRISE EFFORTS AND COLLABORATION THE TECHNOLOGY TRANSFER OFFICE (TTO) FACILITATES AND ACCELERATES THE COMMERCIALIZATION OF TGEN'S SCIENTIFIC DISCOVERIES FOR THE BENEFIT OF HUMAN HEALTH BY: o IDENTIFYING, PATENTING AND LICENSING NEW TECHNOLOGY; o FACILITATING ACCESS AND EXCHANGE OF RESEARCH MATERIALS, TECHNOLOGIES, AND DATA VIA MATERIAL TRANSFER AGREEMENTS (MTAS) OR CONFIDENTIAL DISCLOSURE AGREEMENTS (CDAS); o NEGOTIATING COLLABORATIVE RESEARCH AGREEMENTS; AND o ASSISTING IN THE FORMATION OF START-UP COMPANIES WHEN APPROPRIATE. INVENTION DISCLOSURES TGEN SCIENTISTS WORK WITH THE OFFICE OF TECHNOLOGY TRANSFER (OTT) TO FILE INVENTION DISCLOSURES AS THE FIRST STEP TOWARD A POSSIBLE PATENT APPLICATION OR OTHER APPROPRIATE FORM OF INTELLECTUAL PROPERTY PROTECTION. TGEN FILED 27 INVENTION DISCLOSURES IN FY11 BASED ON DISCOVERIES STEMMING FROM TGEN-LED RESEARCH AND FILED 29 PROVISIONAL PATENT APPLICATIONS.
COMMERCIALIZATION / SPIN OFFS		TGEN'S OFFICE OF BUSINESS DEVELOPMENT WORKS TO DEVELOP AN APPROPRIATE ADMINISTRATIVE STRUCTURE TO HANDLE COMMERCIALIZATION OF ITS INTELLECTUAL PROPERTY, AS WELL AS DEVELOP EFFECTIVE WAYS TO PARTNER WITH THE COMMERCIAL SECTOR. FY11 ACTIVITIES INCLUDED: AS MENTIONED IN THE INTRODUCTION, TGEN LICENSED ITS FIRST DRUG IN MAY 2011. ONCO-101 IS A UNIQUE COMPOUND THAT TARGETS CANCER TUMORS BY MODIFYING THE ACTIONS OF PROTEINS. ONCO-101 MAY PROVE EFFECTIVE AGAINST OVARIAN AND ENDOMETRIAL CANCER. ONCOHOLDINGS, IN TURN, HAS CONTRACTED WITH A TGEN SUBSIDIARY, SCOTTSDALE-BASED TGEN DRUG DEVELOPMENT (TD2), TO HELP GUIDE CONTINUED PRE-CLINICAL TESTING AND EVENTUALLY MOVE ONCO-101 INTO FIRST IN-HUMAN CLINICAL TRIALS, WHERE IT COULD IMMEDIATELY HELP CANCER PATIENTS. ANNAI SYSTEMS ACQUIRED MEDTRUST ONLINE LLC, A SPIN OUT OF TGEN IN 2008. THE COMBINED ENTERPRISE WILL PROVIDE A UNIQUE COMBINATION OF A RICH DATABASE OF INFORMATION REGARDING ONCOLOGY-FOCUSED DRUGS, WITH A UNIQUE ENTERPRISE SOLUTION INCORPORATING BOTH HIGH SPEED AND HIGH CAPACITY EXCHANGE OF INFORMATION. TGEN'S PROTEOMIC CENTER (SUPPORTED BY THE FLINN FOUNDATION) WAS ONE OF TWELVE SITES SELECTED AS A "CENTER OF INNOVATION" BY THE WATER'S CORPORATION, A GLOBAL LEADER IN THE DEVELOPMENT AND MANUFACTURING OF INSTRUMENTATION FOR PROTEOMICS ANALYSIS. IN ADDITION TO INSTRUMENTATION ALREADY PLACED AT TGEN FOR EVALUATION, TGEN WILL HAVE EARLY ACCESS TO NEW PRODUCTS AND WILL PLAY A VITAL ROLE IN THE ASSESSMENT AND DEVELOPMENT OF NEW PROTEOMICS TECHNOLOGY. TGEN PARTICIPATED IN TWO SMALL BUSINESS INNOVATION RESEARCH (SBIR) GRANT APPLICATIONS: o BIOMATRICA OF SAN DIEGO, CA, A WELL-ESTABLISHED BIOSTABILITY CORPORATION, APPLIED FOR AN SBIR GRANT WITH TGEN AND THE VAN ANDEL RESEARCH INSTITUTE TO DEVELOP A ROOM-TEMPERATURE, ENVIRONMENTALLY SUSTAINABLE SOLUTION WITH THE POTENTIAL TO REVOLUTIONIZE BIOSPECIMEN FIXATION, TRANSPORTATION AND STORAGE. THIS NEW TECHNOLOGY CAN BE SEAMLESSLY INTEGRATED INTO EXISTING COLLECTION AND PROCESSING PLATFORMS. FOR PATIENTS, IT CAN POTENTIALLY PROVIDE THE BASIS FOR MORE COMPREHENSIVE TUMOR MOLECULAR PROFILING AND, ULTIMATELY, APPLIED PERSONALIZED THERAPIES. o TGEN AND 360 VANTAGE, LLC (CHANDLER, AZ) APPLIED FOR AN SBIR GRANT TO COMMERCIALIZE A UNIQUE PATENT PENDING GENOMIC DATA COMPRESSION AND INDEXING TOOL DEVELOPED BY ONE OF TGEN'S BIOINFORMATICIANS. THIS NEW TOOL REDUCES THE SPACE REQUIRED TO STORE GENOMIC DATA BY UP TO 60% AND ORGANIZES THIS INFORMATION IN SUCH A WAY AS TO ALLOW PARALLEL PROCESSING OF THE DATA THAT SIGNIFICANTLY INCREASES THE SPEED OF PROCESSING THESE VERY LARGE DATA FILES. 360 VANTAGE IS A CLOUD COMPUTING SOLUTION PROVIDER AND IS WORKING WITH TGEN TO DEVELOP A COMMERCIALLY AVAILABLE VERSION OF THIS TOOL THAT WOULD BE DEPLOYED IN A CLOUD ENVIRONMENT. PATHOGENE (FLAGSTAFF, AZ) PARTNERED WITH TGEN AND NACET (NORTHERN ARIZONA CENTER FOR EMERGING TECHNOLOGIES) TO SUBMIT A GRANT APPLICATION IN JANUARY 2012 FOR AN ARIZONA COMMERCE AUTHORITY RURAL DEVELOPMENT GRANT TO DEVELOP A VALLEY FEVER TESTING LABORATORY BASED ON IP DEVELOPED AT TGEN AND LICENSED TO PATHOGENE. THE PREPARATORY WORK FOR THIS GRANT WAS DONE IN THE LAST QUARTER OF 2011. THE AWARD NOTICE IS DUE FEBRUARY 15TH, 2012. IN COLLABORATION WITH PRICEWATERHOUSECOOPERS (PWC), TGEN CONDUCTED A SIX MONTH MARKET ANALYSIS AND DEVELOPMENT OF A GO TO MARKET PLAN FOR A CLINICAL BIOINFORMATICS SOLUTION. TGEN IS PLANNING TO LAUNCH A "PROOF OF CONCEPT" COMMERCIAL PROTOTYPE OF THIS SOLUTION THROUGH TGEN ACCELERATORS IN Q1 OF 2012. THE MARKET ANALYSIS WAS DRIVEN BY THE NUMEROUS REQUESTS FROM HIGHLY CREDIBLE INDUSTRY LEADERS PURSUING SOLUTIONS FOR CLINICAL BIOINFORMATICS FOR A VARIETY OF APPLICATIONS. TGEN CONTINUES TO ACTIVELY EXPLORE THESE OPPORTUNITIES WHILE REFINING THE BUSINESS MODEL AND VALIDATING THE PLAN'S ASSUMPTIONS THROUGH INTERNAL "PROOF OF CONCEPT" ACTIVITIES. TGEN, US ONCOLOGY, AND LIFE TECHNOLOGIES CONTINUED THEIR GROUNDBREAKING COLLABORATION ON A TRIPLE NEGATIVE BREAST CANCER PILOT CLINICAL TRIAL PROJECT TO PROVIDE DEFINITIVE PROOF OF CONCEPT THAT NEXT GENERATION SEQUENCING TECHNOLOGY COULD SUPPORT PRECISION MEDICAL GENOMICS APPLICATIONS. DUE TO THE COMPLEXITIES OF COMBINING COMPONENTS OF A CLINICAL TRIAL WITH PATIENT DATA ANALYSIS AND INTERPRETATION THIS STUDY HAS SPANNED SEVERAL YEARS, WITH THE BULK OF THE WORK BEING DONE IN FY11. THIS PILOT TRIAL PROJECT HAS PROVIDED A VALUABLE OPPORTUNITY TO LEVERAGE TGEN'S UNIQUE CLINICAL EXPERIENCE TO GUIDE THE DEVELOPMENT OF A MORE COMPLETE AND COMPREHENSIVE GENOMICS SOLUTION THAT CAN POTENTIALLY SUPPORT CLINICAL DECISION MAKING FOR THE TREATMENT OF THIS DISEASE.
CONTRACTS AND COLLABORATIONS		TGEN SIGNED A TOTAL OF 394 AGREEMENTS IN FY11, BROKEN DOWN AS FOLLOWS: 1. TGEN SIGNED 70 CONFIDENTIAL DISCLOSURE AGREEMENTS (CDA) IN FY11. CDAS CREATE A CONFIDENTIAL RELATIONSHIP BETWEEN TGEN AND A HOST OF POTENTIAL COLLABORATORS/PARTNERS. WHILE NOT ALL CDAS RESULT IN A FORMAL COLLABORATION OR PARTNERSHIP, THEY DO PROVIDE A NUMBER OF INSTITUTES AND COMPANIES (LOCALLY, NATIONALLY AND INTERNATIONALLY) A GREATER PICTURE OF TGEN'S CAPABILITIES AND REFLECT POSITIVELY AS A WHOLE ON ARIZONA'S BIOMEDICAL SCIENCE PURSUITS. 2. TGEN SIGNED 83 MATERIAL TRANSFER AGREEMENTS (MTA) IN FY11. MTAS FORM THE BACKBONE OF NUMEROUS TGEN RESEARCH COLLABORATIONS AS SHARED MATERIALS INCLUDE REAGENTS, CELL LINES, SOFTWARE AND MORE. 3. TGEN SIGNED 67 RESEARCH COLLABORATIONS (MANY WITH LOCAL AND STATE AFFILIATIONS), INCLUDING AGREEMENTS THAT FURTHER RESEARCH INTO A HOST OF DISEASES, INCLUDING BRAIN CANCER, MELANOMA, ALZHEIMER'S AND AUTISM. 4. ADDITIONALLY, TGEN SIGNED AN ADDITIONAL 170 AGREEMENTS CONSISTING OF CONSULTING AND PROFESSIONAL SERVICES AGREEMENTS, COMMERCIALIZATION LICENSES, MEMORANDUMS OF UNDERSTANDING, LEASES, AND EVALUATION AGREEMENTS. FY11 SELECT HIGHLIGHTS 1. UNIVERSITY HOSPITAL OF BASEL - "CLONAL PROFILING OF TUMORS OF UNKNOWN ORIGIN" (DRS. BARRETT & BUBENDORF) 2. HILLS PET NUTRITION RESEARCH - "CONTINUATION OF CANINE AND FELINE PHENOTYPIC DATA ANALYSIS AND ADDITIONAL GENOTYPING" (DR. HUENTELMAN) 3. ILLUMINA AMENDMENT ONE TO UMBRELLA AGREEMENT - EXTENDS TERM THROUGH 6/2/13 4. M.D. ANDERSON CANCER CENTER AMENDMENT THREE TO IVY CONSORTIUM RESEARCH COLLABORATION CONTRACT - MODIFIES STATEMENT OF WORK AND SITE BUDGET 5. UNIVERSITY OF TENNESSEE RESEARCH COLLABORATION AGREEMENT - UMBRELLA AGREEMENT COVERING PROJECTS RELATED TO THE COMPARATIVE ONCOLOGY TRIAL CONSORTIUM (COTC) 6. CATHOLIC HEALTHCARE WEST RESEARCH PLAN 06 - "EVALUATION OF RNA ISOLATION METHODS FROM HUMAN CSF" (DRS. BOMPREZZI & JENSEN) 7. VAN ANDEL RESEARCH PLAN - "DEVELOPMENT OF GENOMIC-BASED PREDICTORS OF DRUG 8. "RESPONSE IN PANCREATIC CANCER" (DRS. POSNER & WEBB) 9. VAN ANDEL-ORTHOPAEDIC ASSOCIATES OF MICHIGAN RESEARCH COLLABORATION AGREEMENT - FOR GENOME-WIDE ASSOCIATION STUDY OF BONE-GROWTH GERMLINE GENETIC MARKERS (DRS. WILLIAMS, CRAIG & JONES) 10. UNIVERSITY OF MINNESOTA RESEARCH COLLABORATION AGREEMENT - UMBRELLA AGREEMENT COVERING PROJECTS RELATED TO THE COMPARATIVE ONCOLOGY TRIAL CONSORTIUM (COTC) 11. SCOTTSDALE HEALTHCARE RESEARCH PLAN 05 - "MOLECULAR ANALYSIS OF ENDOCRINE TUMORS" (DRS. BUSSEY & DEMEURE) 12. UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. RESEARCH COLLABORATION AGREEMENT - UMBRELLA AGREEMENT COVERING PROJECTS RELATED TO THE COMPARATIVE ONCOLOGY TRIAL CONSORTIUM (COTC) 13. MULTIPLE MYELOMA RESEARCH CONSORTIUM AMENDMENT 3 TO RESEARCH AGREEMENT - EXTENDS TERM THROUGH DECEMBER 31, 2011, AND AMENDS MILESTONE PAYMENTS TO BROAD 14. PURDUE UNIVERSITY RESEARCH COLLABORATION AGREEMENT - UMBRELLA AGREEMENT COVERING PROJECTS RELATED TO THE COMPARATIVE ONCOLOGY TRIAL CONSORTIUM (COTC) 15. ASTRAZENECA AMENDMENT 1 TO RESEARCH PLAN AZ02 - EXTENDS TERM THROUGH JULY 11, 2012 16. MICHIGAN STATE UNIVERSITY RESEARCH COLLABORATION AGREEMENT - UMBRELLA AGREEMENT COVERING PROJECTS RELATED TO THE COMPARATIVE ONCOLOGY TRIAL CONSORTIUM (COTC) 17. UNIVERSITY OF LUXEMBOURG RESEARCH COLLABORATION AGREEMENT - PROJECT ENTITLED "GENOMIC ANALYSIS OF WASTEWATER LIPID - ACCUMULATING BACTERIAL CONSORTIA" (DRS. KEIM/PRICE & WILMES) 18. TUFTS UNIVERSITY - UMBRELLA AGREEMENT COVERING PROJECTS RELATED TO THE COMPARATIVE ONCOLOGY TRIAL CONSORTIUM (COTC) 19. MAYO STATEMENT OF WORK #4 - "EPIGENETICS OF DIET AND NEURODEGENERATION" (DRS. DUNCKLEY & DRIVER-DUNCKLEY/CASELLI/ADLER) 20. CASE WESTERN RESERVE UNIVERSITY RESEARCH COLLABORATION AGREEMENT - UMBRELLA AGREEMENT COVERING FUTURE JOINT RESEARCH PROJECTS CONCERNING DISCOVERY OF BIOMARKERS IN BRAIN TUMORS (DR. BERENS) 21. UNIVERSITY OF CALIFORNIA DAVIS RESEARCH COLLABORATION AGREEMENT - UMBRELLA AGREEMENT COVERING PROJECTS RELATED TO THE COMPARATIVE ONCOLOGY TRIAL CONSORTIUM (COTC) 22. MAYO CLINIC AMENDMENT TO MASTER RESEARCH AGREEMENT - ADDS THE "SEED GRANT PROGRAM" PROVISION. 23. MAYO CLINIC THIRD AMENDMENT TO RESEARCH COLLABORATION CONTRACT FOR IVY CONSORTIUM - EXTENDS TERM THROUGH 1/31/12 (DR. BERENS). 24. PATHOGENE FIRST AMENDMENT TO RESEARCH PLAN 04 ("CANINE VALLEY FEVER MOLECULAR DIAGNOSIS STUDY") - CHANGES TITLE OF PROJECT TO "ASSAY EVALUATION BY EXTERNAL COMPANIES"; AMENDS TERM AND COSTS OF STUDY; INCORPORATES TECHNICAL PLAN (DR. PRICE). 25. SCOTTSDALE HEALTHCARE FIRST AMENDMENT TO RESEARCH PLAN 01 ("DIAGNOSTIC MIRNAS FOR PANCREATIC CANCER FROM BLOOD SAMPLES") - ADDS PCRT ACKNOWLEDGEMENT OF MATERIAL PROVISION TO STUDY (DR. WEISS). 26. UNIVERSITY OF TENNESSEE RESEARCH COLLABORATION AGREEMENT - UMBRELLA JOINT AGREEMENT COVERING FUTURE RESEARCH PROJECTS. 27. COLORADO STATE UNIVERSITY RESEARCH COLLABORATION AGREEMENT - UMBRELLA AGREEMENT COVERING PROJECTS RELATED TO THE COMPARATIVE ONCOLOGY TRIAL CONSORTIUM (COTC). 28. UNIVERSITY OF WISCONSIN - MADISON RESEARCH COLLABORATION AGREEMENT - UMBRELLA AGREEMENT COVERING PROJECTS RELATED TO THE COMPARATIVE ONCOLOGY TRIAL CONSORTIUM (COTC). 29. CATHOLIC HEALTHCARE WEST RESEARCH PLAN 04 - "EVALUATION OF RNA ISOLATION METHODS FROM HUMAN CSF" (DRS. JENSEN & BOMPREZZI). 30. SCRIPPS RESEARCH RCA & RESEARCH PLAN - "GENOMIC CHARACTERIZATION OF PRIMARY, LOCALLY RECURRENT AND METASTATIC DISEASE FROM A PATIENT WITH METAPLASTIC INFLAMMATORY BREAST CANCER." (DRS. HEATHER CUNLIFFE & BRUNHILDE FELDING-HABERMANN). 31. CATHOLIC HEALTHCARE WEST RESEARCH PLAN 05 - "MEASURE INTRA-TUMOR PH IN BOTH PRIMARY XENOGRAFT AND TRANSGENIC MOUSE MODELS." (DRS. CLIFF WHATCOTT & GREGORY TURNER). 32. HILLS PET NUTRITION RESEARCH PLAN RP01 - "CANINE GENOTYPING & DEVELOPMENT OF A PHENOTYPIC DATA PRIORITY LIST." (DR. MATTHEW HUENTELMAN). 33. HILLS PET NUTRITION RESEARCH PLAN RP02 - "FELINE GENOTYPING & DEVELOPMENT OF A PHENOTYPIC DATA PRIORITY LIST." (DR. MATTHEW HUENTELMAN). 34. ONCOHOLDINGS INC. - TD2 RESEARCH COLLABORATION AGREEMENT - FOR FUTURE COLLABORATIONS USING TD2 AS PREFERRED PROVIDER FOR PRECLINICAL, CLINICAL AND REGULATORY SERVICES. 35. PATHOGENE AMENDMENT 1 TO MASTER RESEARCH AGREEMENT - EXTENDS TERM THROUGH NOV. 14, 2012. 36. MAYO CLINIC STATEMENT OF WORK 01 - "A PILOT STUDY EXAMINING THE UTILITY OF WHOLE GENOME TUMOR SEQUENCING (WGS) AND WHOLE GENOME EXPRESSION PROFILE TO FIND POTENTIAL TARGETS FOR THERAPY IN PATIENTS WITH ADVANCED CANCER" (DRS. RAMESH RAMANATHAN & KEITH STEWART). 37. CHILDREN'S HOSPITAL LOS ANGELES AMEND TO COLLABORATION AGREEMENT - EXTENDS TERM THROUGH JAN. 10, 2012. 38. PHOENIX CHILDREN'S HOSPITAL RESEARCH COLLABORATION AGREEMENT - UMBRELLA JOINT RESEARCH AGREEMENT COVERING FUTURE PROJECTS. 39. ASTRAZENECA RESEARCH PLAN AZ02 - "DETECTION OF STRUCTURAL REARRANGEMENTS, INCLUDING GENE FUSION CANDIDATES IN BREAST CARCINOMA GENOMES." 40. BANNER RESEARCH INSTITUTE RESEARCH PLAN 01 - "COMPARE CHANGES IN RNA EXPRESSION AS BIOMARKERS FOR ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE, A COMPARISON OF CSF AND BLOOD." 41. ADAMAS AMENDMENT 9 TO COLLABORATION AGREEMENT - REVISES WORK-PLAN AND EXTENDS TERM THROUGH JAN. 31, 2011. 42. ASTRAZENECA AMENDMENT 1 TO RESEARCH AGREEMENT - EXTENDS TERM THROUGH DEC. 12, 2012.
JOB CREATION / ROI		20 NEW FULL-TIME EQUIVALENT POSITIONS WERE CREATED IN FY11 WITH SALARIES AND BENEFITS TOTALING APPROXIMATELY $1,330,161. STUDENT SALARIES WERE JUST OVER $374,000, BRINGING THE OVERALL TOTAL TO $1,704,161. TGEN STAFF TOTALED 261, OF WHICH 86 PERCENT HOLD A COLLEGE DEGREE (49 PERCENT HOLD AN ADVANCED DEGREE). FY11 POSITIONS FILLED INCLUDE: ADMINISTRATIVE ASSISTANT; ASSOCIATE PROFESSOR; BIOINFORMATICIAN; ASSOCIATE CLINICAL DATA COORDINATOR; KNOWLEDGE COMPUTING ARCHITECT; JR. PROJECT MANAGER; POST-DOC FELLOW; RESEARCH ASSOCIATE; RESEARCH ASSOCIATE II; STAFF SCIENTIST; VICE PRESIDENT, TGEN FOUNDATION WE HAVE STRESSED IN THE PAST THAT INTERNSHIPS SERVE AS A PIPELINE TO TGEN IN TERMS OF FUTURE RECRUITMENT AND SUPPORT OF THE STATEWIDE INITIATIVE TOWARDS EDUCATION AND DEVELOPMENT FOR THE STUDENTS IN THE LIFE SCIENCES. ADDITIONALLY, TGEN IS A PROVING GROUND WHERE TALENTED UNDERGRADUATES GAIN VALUABLE EXPERIENCE PRIOR TO RETURNING TO EARN ADVANCED DEGREES IN THE BIOMEDICAL SCIENCES. IN FY11, 9 EMPLOYEES RETURNED TO UNIVERSITY TO FURTHER THEIR BIOMEDICAL EDUCATION, WITH 4 OF THE 9 CHOOSING AN ARIZONA-BASED UNIVERSITY. (TOTALING NEARLY 500 IN NUMBER), AS WELL AS SENT REPRESENTATIVES INTO THE COMMUNITY TO PRESENT AT FUNCTIONS, CAREER AND EDUCATIONAL FAIRS. TOUR REQUESTS MAY BE SUBMITTED VIA THE WEBSITE AT: HTTP://WWW.TGEN.ORG/EDUCATION/TOUR_REQUEST.CFM RETURN ON STATE INVESTMENT IN LATE 2011, IN THE THIRD SUCH STUDY FOR TGEN, TRIPP UMBACH CONCLUDED WHEN THE IMPACT OF TGEN-GENERATED BUSINESS SPIN-OFFS AND COMMERCIALIZATION ARE INCLUDED, TGEN IN 2010 PRODUCED $25.04 FOR EVERY $1 INVESTED BY THE STATE OF ARIZONA, SUPPORTED 1,124 JOBS, GENERATED $10.1 MILLION IN STATE TAX REVENUES, AND PRODUCED $137.7 MILLION IN TOTAL ANNUAL ECONOMIC IMPACT ON ARIZONA. TRIPP UMBACH PREDICTS SIGNIFICANT CONTINUED GROWTH IN THE FUTURE. EDUCATION AND PUBLIC OUTREACH INTERNSHIPS TGEN, THROUGH ITS EDUCATION AND OUTREACH PROGRAMS, SEEKS TO INCREASE THE WORKING KNOWLEDGE OF GENOMICS WITHIN THE COMMUNITY AT LARGE AND TO HELP EDUCATE, TRAIN, AND INSPIRE THE NEXT GENERATION OF RESEARCHERS AND PHYSICIANS. THE MAJOR PROGRAMMATIC FOCUS OF TGEN'S EDUCATION EFFORTS CENTERS ON THE HELIOS SCHOLARS PROGRAM AT TGEN, AN ANNUAL SUMMER INTERNSHIP PROGRAM THAT PAIRS A STUDENT WITH A TGEN SCIENTIST/MENTOR THAT PROVIDES HANDS-ON LABORATORY TRAINING. TGEN ALSO OFFERS AN ACADEMIC YEAR INTERNSHIP PROGRAM, PROVIDING A LIMITED NUMBER OF VOLUNTEER INTERNSHIP POSITIONS DURING THE ACADEMIC YEAR, BASED ON THE NEEDS AND PROJECTED WORKLOAD OF THE HOST LABORATORIES. EFFORTS ARE CURRENTLY UNDERWAY TO ESTABLISH A FORMAL ACADEMIC YEAR INTERNSHIP PROGRAM. BY ALL ACCOUNTS, 2011 WAS A SUCCESSFUL YEAR WITH 45 BIOSCIENCE STUDENTS COMPLETING THE 2011 HELIOS SCHOLARS PROGRAM AT TGEN, AND 48 NON-HELIOS STUDENTS CONDUCTING INTERNSHIPS - SCIENTIFIC AND ADMINISTRATIVE - IN A NUMBER OF TGEN LABS AND DEPARTMENTS. WHILE NUMEROUS SUMMER JOBS OFFER STUDENTS THE OPPORTUNITY TO EARN MONEY, TGEN INTERNSHIPS PROVIDE AN EXPERIENTIAL LEARNING OPPORTUNITY FOR STUDENTS TO BUILD ON THEIR ACADEMIC STUDIES. UNDER THE GUIDANCE OF EXPERIENCED MENTORS, AN ACTIVE GROUP OF LIKE-MINDED STUDENTS EXPLORE AND LEARN FIRST HAND TECHNIQUES AND PROCESSES THAT EXPOSE THEM TO THE LATEST IN GENOMIC RESEARCH. THIS TRAINING OFTEN SOLIDIFIES A STUDENTS' CAREER CHOICE AND, IN MANY WAYS, BECOMES THE SPRINGBOARD TO THEIR FUTURE IN THE BIOMEDICAL SCIENCES. TWENTY-SEVEN FEMALES AND 18 MALES COMPRISED THE HELIOS SCHOLARS, BROKEN DOWN AS FOLLOWS: 15 PERCENT HIGH SCHOOL, 76 PERCENT UNDERGRADUATE, AND 9 PERCENT GRADUATE/MEDICAL SCHOOL. TEACHER TRAINING PROGRAM IN FY11, TGEN COMPLETED ITS FOURTH YEAR OF A 5-YEAR TRAINING AWARD IN COLLABORATION WITH NORTHERN ARIZONA UNIVERSITY TO CONDUCT A SUMMER GENOMICS WORKSHOP FOR TEACHERS AND GRADUATE STUDENTS AS PART OF AN NSF GRANT CALLED BIOTECHNOLOGY INTEGRATION OPPORTUNITIES FOR TEACHER EDUCATION AND CONTENT (BIOTEC). THIS GRANT PARTNERS THE COLLEGE OF ENGINEERING AND NATURAL SCIENCES, THE COLLEGE OF EDUCATION AT NORTHERN ARIZONA UNIVERSITY, AND TGEN IN ORDER TO ENHANCE INQUIRY-BASED SCIENCE TEACHING IN GRADES 5, 7, AND 9 WHILE EXPANDING THE INTERDISCIPLINARY PREPARATION OF GRADUATE STUDENTS IN BIOTECHNOLOGY. THE WORKSHOP IS DESIGNED TO UPDATE TEACHERS AND FELLOWS ON GENOMIC SCIENCE, THE CONTINUING EFFORT TO FIND THE GENETIC BASIS OF VARIOUS DISEASES AND DISORDERS, AND TO PRESENT CURRENT TOPICS ON THE ETHICAL, LEGAL, AND SOCIAL IMPLICATIONS OF GENOMICS. CAREERS AND ESSENTIAL RESEARCH SKILLS WILL BE EMPHASIZED DURING THE PROGRAM CULMINATING ACTIVITY. TEACHERS WILL LEARN TO INCORPORATE ALL OF THIS INFORMATION IN THE BIOSCIENCES INTO THEIR CLASSROOMS. EDUCATIONAL AND PUBLIC TOURS TGEN VALUES THE OPPORTUNITY TO SHARE ITS STATE-OF-THE-ART RESEARCH FACILITY WITH THE COMMUNITY THROUGH PUBLIC TOURS OF TGEN. THE COMMUNITY'S INTEREST IN TOURS CONTINUES TO GROW. IN FY11, TGEN HOSTED NUMEROUS PUBLIC TOURS FOR A DIVERSE RANGE OF COMMUNITY MEMBERS AND ORGANIZATIONS (TOTALING NEARLY 500 IN NUMBER), AS WELL AS SENT REPRESENTATIVES INTO THE COMMUNITY TO PRESENT AT FUNCTIONS, CAREER AND EDUCATIONAL FAIRS. TOUR REQUESTS MAY BE SUBMITTED VIA THE WEBSITE AT: HTTP://WWW.TGEN.ORG/EDUCATION/TOUR_REQUEST.CFM
STIMULATING GROWTH OF ARIZONA'S LIFE SCIENCE INDUSTRIES		AN IMPORTANT FACTOR IN CONTINUING TGEN'S SUCCESS IS COMMUNICATION WITH VARIOUS STAKEHOLDERS AND THE BROADER ARIZONA COMMUNITY. TOWARD THAT GOAL, TGEN SR. LEADERSHIP PARTICIPATES IN A MYRIAD OF COMMUNITY-RELATED ACTIVITIES THROUGH PRESENTATIONS AT REGIONAL MEETINGS AND AS A MEMBER OR PARTICIPANT OF VARIOUS COMMITTEES AND GROUPS, INCLUDING THE ARIZONA ALZHEIMER'S CONSORTIUM BOARD, ARIZONA BIOSCIENCE ROADMAP STEERING COMMITTEE AND ARIZONA BIOSCIENCE ROADMAP EDUCATION & WORKFORCE DEVELOPMENT COMMITTEE, ARIZONA TECHNOLOGY COUNCIL, GREATER PHOENIX LEADERSHIP, NSF STEP GRANT ADVISORY BOARD- FOR ESTRELLA MOUNTAIN CC, AND A MEMBER OF ARIZONA SCIENCE CENTER PATHWAYS TO DISCOVERY GRANT (NOW IN YEAR 3). MEDIA TGEN REMAINS ACTIVE IN PURSING POSITIVE EARNED MEDIA EXPOSURE FOR THE INSTITUTE'S RESEARCH AND PHILANTHROPIC ACTIVITIES. MEDIA EXPOSURE RAISES AWARENESS AND BRINGS ADDED CREDIBILITY TO THE INSTITUTE AND THE STATE. IN TOTAL, TGEN RECEIVED GREATER THAN 1,100 MEDIA MENTIONS IN FY11 IN VARIOUS TRADE AND PUBLIC MEDIA: LOCALLY, NATIONALLY AND INTERNATIONALLY. WHILE CITING TGEN SPECIFICALLY, THESE ARTICLES AND NEWS BRIEFS HELP BUILD A GREATER PRESENCE FOR THE CONTINUOUSLY EXPANDING BIOMEDICAL SCIENCE INITIATIVES OCCURRING IN ARIZONA. MEDIA OUTLETS INCLUDE: USA TODAY ORLANDO SENTINEL THE HOUSTON CHRONICLE THE ARIZONA REPUBLIC PHOENIX BUSINESS JOURNAL ARIZONA BUSINESS GAZETTE ARIZONA DAILY STAR JEWISH NEWS OF GREATER PHOENIX GRAND RAPIDS PRESS PLAIN DEALER (CLEVELAND) UPI NATIONAL PUBLIC RADIO NEW YORK TIMES WALL STREET JOURNAL LOS ANGELES TIMES LA WEEKLY REUTERS TIME MAGAZINE BOSTON GLOBE NEWSDAY AGENCE FRANCE PRESSE WIRED MAGAZINE CNN CNN INTERNATIONAL ONLINE TGEN'S ONLINE PRESENCE CONTINUES TO INCREASE ON AN ANNUAL BASIS. WITH TWO ACTIVE SITES (TGEN AND THE TGEN FOUNDATION) MORE THAN 1.5 MILLION PAGE VIEWS WERE RECORDED IN FY11. THE WEBSITE SERVES AS A PORTAL TO ALLOW ARIZONANS - AND OTHERS WORLDWIDE- TO LEARN ABOUT THE RESEARCH AND DISCOVERIES COMING OUT OF TGEN LABS. ADDITIONALLY, THE TGEN FOUNDATION WEB PAGES ALLOW SUPPORTERS TO CREATE MEMORIALS AND FUNDRAISING PAGES IN SUPPORT OF TGEN'S EFFORTS TO DEVELOP IMPROVED DIAGNOSTIC TOOLS AND NEW THERAPEUTICS THAT TARGET A HOST OF DISEASES. IN TERMS OF SOCIAL MEDIA, TGEN'S FACEBOOK AND TWITTER AUDIENCES ARE GROWING AND PROVIDE A FURTHER OPPORTUNITY TO COMMUNICATE WITH NUMEROUS CONSTITUENCIES THROUGH EVER-INCREASING MEDIUMS. GROWING AND PROVIDE A FURTHER OPPORTUNITY TO COMMUNICATE WITH NUMEROUS CONSTITUENCIES THROUGH EVER-INCREASING MEDIUMS.
GOVERNANCE STRUCTURE	FORM 990, PART VI, LINES 6, 7A & 7B	LINE 6 - THE SOLE CORPORATE MEMBER OF TGEN FOUNDATION IS THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN). Effective December 1, 2009, TGEN entered into an alliance and affiliation agreement (the Affiliation Agreement) with the Van Andel Research Institute (VARI), a Michigan charitable trust exempt from tax under Section 501(c)(3) of the Internal Revenue Code. TGEN changed from a director-based, nonprofit organization to a member-based, nonprofit organization, whereby VARI became the sole member of TGEN. VARI agreed to supplement the Institute's funding efforts by providing $10.0 million per year, for three consecutive years, in unrestricted support. Effective March 12, 2012, TGen and VARI agreed to terminate their Affiliation Agreement, and TGen converted from a member-based, Arizona nonprofit corporation to a director-based, Arizona nonprofit corporation, whereby VARI is no longer the sole member of TGen. LINE 7A - TGEN, AS THE SOLE CORPORATE MEMBER OF TGEN FOUNDATION, HAS THE RIGHT TO ELECT THE BOARD OF DIRECTORS OF TGEN FOUNDATION. LINE 7B - THE SOLE CORPORATE MEMBER'S VOTE SHALL BE REQUIRED ON: A) THE ELECTION AND REMOVAL OF ELECTED DIRECTORS AS SET FORTH IN THE BYLAWS; B) THE ADOPTION OF ANY PLAN OF MERGER OR CONSOLIDATION; C) THE SALE OF ALL OR SUBSTANTIALLY ALL THE FOUNDATION'S ASSETS IN A SINGLE TRANSACTION OR SERIES OF RELATED TRANSACTIONS; D) THE AMENDMENT OF THE FOUNDATION'S ARTICLES OF INCORPORATION OR BYLAWS; E) THE INSTITUTION, OR CONSENT TO INSTITUTION, OF PROCEEDINGS TO ADJUDICATE THE FOUNDATION BANKRUPT OR INSOLVENT, OR THE FILING OF A PETITION SEEKING OR CONSENTING TO REORGANIZATION OR RELIEF UNDER ANY LAW RELATING TO BANKRUPTCY, INSOLVENCY, OR OTHER RELIEF FOR DEBTORS, OR THE CONSENT TO THE APPOINTMENT OF A RECEIVER, LIQUIDATOR, ASSIGNEE, TRUSTEE, SEQUESTRATOR (OR SIMILAR OFFICIAL) OF THE FOUNDATION OR OF ALL OR ANY SUBSTANTIAL PART OF ITS PROPERTY, OR THE MAKING OF ANY ASSIGNMENT FOR THE BENEFIT OF CREDITORS, OR THE ADMISSION IN WRITING OF THE FOUNDATION'S INABILITY TO PAY ITS DEBTS GENERALLY AS THEY BECOME DUE, OR ANY STEPS IN FURTHERANCE OF SUCH ACTION; AND F) THOSE MATTERS UPON WHICH THE MEMBER IS GRANTED VOTING RIGHTS IN THE ARTICLES OF INCORPORATION, BYLAWS, OR THE ARIZONA NONPROFIT CORPORATION ACT. THE SOLE CORPORATE MEMBER HAS THE FOLLOWING RESERVE POWERS: A) APPOINT AND REMOVE THE PRESIDENT; B) APPROVE THE ESTABLISHMENT OF NEW CORPORATE PARTNERSHIP ENTITIES CREATED OR JOINED BY THE FOUNDATION; C) APPROVE THE FOUNDATION'S EXECUTION OF MATERIAL CONTRACTS; AND D) APPROVE THE FOUNDATION'S INCURRENCE OF MATERIAL DEBTS. VAN ANDEL RESEARCH INSTITUTE, AS THE SOLE MEMBER OF TGEN, APPOINTS ELECTED DIRECTORS TO TGEN'S BOARD OF DIRECTORS FROM A LIST OF INDIVIDUALS PRESENTED BY THE NOMINATING COMMITTEE.
PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990	FORM 990, PART VI, LINE 11A	THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE FINANCE DEPARTMENT. THE 990 IS THEN REVIEWED BY MANAGEMENT IN THE FINANCE DEPARTMENT AND IS POSTED ON THE BOARD WEBSITE PRIOR TO FILING WITH THE IRS. BY MANAGEMENT IN THE FINANCE DEPARTMENT AND IS POSTED ON THE BOARD WEBSITE PRIOR TO FILING WITH THE IRS.
PROCESS USED TO MONITOR TRANSACTIONS FOR CONFLICTS OF INTEREST	FORM 990, PART VI, LINE 12C	TGEN FOUNDATION ISSUES A CONFLICT OF INTEREST QUESTIONNAIRE ON AN ANNUAL BASIS TO ALL FOUNDATION DIRECTOR LEVEL POSITIONS AND ABOVE IN ADDITION TO ANY KEY EMPLOYEES DESIGNATED BY THE FOUNDATION PRESIDENT AND/OR CHIEF OPERATING OFFICER. THE QUESTIONNAIRES ARE REVIEWED BY THE CHIEF FINANCIAL OFFICER AND THOSE EMPLOYEES WITH CONFLICTS ARE SENT FOR FURTHER REVIEW TO THE FOUNDATION PRESIDENT AND/OR CHIEF OPERATING OFFICER TO ENSURE A PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS NEEDED BASIS BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION.
PROCESS USED TO DETERMINE COMPENSATION	FORM 990, PART VI, LINES 15A AND 15B	TGEN FOUNDATION DOES NOT HAVE ANY DIRECT EMPLOYEES. COMPENSATION IS DETERMINED BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) USING THE FOLLOWING PROCESS: TGEN'S GOVERNANCE AND EXECUTIVE COMPENSATION COMMITTEE WILL ACT IN AN "ADVICE AND CONSENT" CAPACITY REVIEWING THE RECOMMENDATIONS FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR REGARDING THE COMPENSATION OF DISQUALIFIED PERSONS AND FORWARDING FINAL RECOMMENDATIONS TO THE FULL BOARD FOR APPROVAL. DISQUALIFIED PERSONS (EXCEPT FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR) WILL NOT BE PRESENT FOR, OR PARTICIPATE IN, COMMITTEE DELIBERATIONS CONCERNING THEIR COMPENSATION (OTHER THAN TO ANSWER QUESTIONS). THE PRESIDENT AND SCIENTIFIC DIRECTOR WILL PARTICIPATE IN THE DELIBERATIONS CONCERNING THE COMPENSATION OF DIRECT REPORTS. DURING THE DECISION-MAKING PROCESS, THE COMMITTEE WILL ADHERE TO THE EXECUTIVE COMPENSATION PHILOSOPHY. THE COMMITTEE IS AUTHORIZED (AND PROVIDED WITH SUFFICIENT FUNDING) TO ANNUALLY ENGAGE OUTSIDE INDEPENDENT COMPENSATION AND LEGAL ADVISORS WHEN DEEMED NECESSARY AND ADVISABLE. THE COMMITTEE WILL COMPLY WITH THE "REBUTTABLE PRESUMPTION OF REASONABLENESS" UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE WHENEVER POSSIBLE. THE COMMITTEE WILL REVIEW AND UNDERSTAND THE INTERNAL REVENUE CODE PROVISIONS DEALING WITH "EXCESS BENEFIT TRANSACTIONS CONCERNING DISQUALIFIED PERSONS' COMPENSATION". WHEN DEVELOPING A COMPENSATION PHILOSOPHY, TGEN KEPT IN MIND THE FOLLOWING FACTORS: THE TGEN MISSION AND STRATEGY THE TGEN CULTURE TRENDS IN COMPENSATION IN THE EXTERNAL ENVIRONMENT TRENDS IN RECRUITMENT OF NEW EMPLOYEES TRENDS IN ORGANIZATIONAL EMPLOYEE TURNOVER TGEN'S LIFE CYCLE STAGE
AVAILABILITY OF CERTAIN DOCUMENTS TO THE GENERAL PUBLIC	FORM 990, PART VI LINE 19	TGEN FOUNDATION PROVIDES ITS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY TO THE GENERAL PUBLIC UPON REQUEST.
HOURS DEVOTED TO RELATED ORGANIZATION	FORM 990, PART VII	THE ORGANIZATION DOES NOT DIRECTLY HAVE ANY EMPLOYEES. THE FOLLOWING INDIVIDUALS REPORTED IN PART VII ARE PAID BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN), A RELATED TAX-EXEMPT ORGANIZATION, FOR SERVICES PROVIDED TO TGEN FOUNDATION. THESE INDIVIDUALS DEVOTED HOURS PER WEEK TO THE ORGANIZATIONS AS FOLLOWS: MICHAEL BASSOFF - 16 HOURS TO TGEN; 24 HOURS TO TGEN FOUNDATION; DENISE MCCLINTIC - 0 HOURS TO TGEN, 40 HOURS TO TGEN FOUNDATION. THE FOLLOWING INDIVIDUAL REPORTED IN PART VII IS PAID BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN), A RELATED TAX-EXEMPT ORGANIZATION, FOR SERVICES PROVIDED TO TGEN. THIS INDIVIDUAL DEVOTED 39 HOURS PER WEEK TO TGEN AND 1 HOUR PER WEEK TO TGEN FOUNDATION: TERESA BURLESON THE FOLLOWING INDIVIDUAL REPORTED IN PART VII IS PAID BY VAN ANDEL RESEARCH INSTITUTE (VARI), A RELATED TAX-EXEMPT ORGANIZATION, FOR SERVICES PROVIDED TO TGEN AND TGEN FOUNDATION. THIS INDIVIDUAL DEVOTED 14 HOURS PER WEEK TO TGEN, 2 HOURS PER WEEK TO TGEN FOUNDATION, AND 24 HOURS PER WEEK TO VARI: JEFFREY TRENT

Schedule R IRS990ScheduleR

Form990 Schedule R Part II Form990ScheduleRPartII (2 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EINEIN	Primary ActivitiesPrimaryActivities	Legal Domicile StateLegalDomicileState	Exempt Code SectionExemptCodeSection	Public Charity StatusPublicCharityStatus	Business Name Line1DirectControllingEntityName/BusinessNameLine1
THE TRANSLATIONAL GENOMICS RESEARCH INST
445 NORTH 5TH STREET	PHOENIX	AZ	85004	753065445	RESEARCH	AZ	501(C)(3)	7	VARI
VAN ANDEL RESEARCH INSTITUTE
333 BOSTWICK AVE STE 850	GRAND RAPIDS	MI	49503	522000823	MEDICAL RSCH	MI	501(C)(3)	4	NA

Field	Value	IRS element (for citing)
Receipt Of Int Ann Rents Royalties	false	ReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other Org	true	GiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other Org	false	GiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other Org	false	LoansOrGuaranteesFromOtherOrg
Sale Of Assets To Other Org	false	SaleOfAssetsToOtherOrg
Purchase Of Assets From Other Org	false	PurchaseOfAssetsFromOtherOrg
Exchange Of Assets	false	ExchangeOfAssets
Rental Of Facilities To Other Orgs	false	RentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other Orgs	false	RentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other Orgs	true	PerformOfServicesForOtherOrgs
Perform Of Services By Other Orgs	false	PerformOfServicesByOtherOrgs
Sharing Of Facilities	false	SharingOfFacilities
Sharing Of Paid Employees	false	SharingOfPaidEmployees
Reimbursement Paid To Other Org	false	ReimbursementPaidToOtherOrg
Reimbursement Paid By Other Org	true	ReimbursementPaidByOtherOrg
Other Transfer To Other Org	false	OtherTransferToOtherOrg
Other Transfer From Other Org	false	OtherTransferFromOtherOrg